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Eosinophils
Eosinophils originate from myeloid stem cells, develop in the bone marrow, remain for a short 
period of time in the peripheral blood (6-8h) and then migrate into the tissue 1; 2. The number of 
eosinophils in the blood of healthy individuals is normally quite low, about 1-3% of total leukocytes. 
Paul Ehrlich fi rst recognized the eosinophil in 1879 as cells that contain many granules that stain 
bright red with the acidic dye eosin 3. The cytoplasmic granules that are stained by eosin are the 
main distinguishing feature of eosinophils. These granules contain numerous cytotoxic proteins 
as well as pro- and anti-infl ammatory mediators. Another characteristic of eosinophils is their 
bilobed nucleus. While eosinophils play a benefi cial role in helminth infection, they can also 
cause tissue damage at infl ammatory loci as seen in allergic asthma.
Priming or pre-activation of eosinophils by cytokines and chemokines is critical for optimal 
activation 4. Priming by itself does not induce effector responses of eosinophils but instead 
elevates the activation status of the cell. Upon addition of a second stimulus, the cellular 
responses are much stronger than those induced by the stimulus alone. For example, eosinophils 
primed with interleukin 3 (IL-3), IL-5 or granulocyte-macrophage colony stimulating factor (GM-
CSF) have an enhanced respiratory burst in response to opsonized particles and migrate better 
in response to platelet activating factor 5; 6. 
Figure 1. Multi step model for eosinophil extravasation. Cells roll on activated endothelial 
cells. Activation results in fi rm adhesion interactions with ligands present on the endothelium. 
Finally, the cells spread and migrate across the endothelium cells to the site of infl ammation.
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Eosinophils generally constitute only a small proportion of the total leukocyte number in the blood. 
Concentration gradients of chemotactins and expression of the correct adhesion molecules guide 
the cell out of the bloodstream and into the tissues. The unique combination of these mediators 
results in the selective recruitment of eosinophils. Eosinophil recruitment is a multi-step process, 
including rolling along and attachment to endothelial cells, trans-endothelial diapedesis, and 
migration into the tissue (fi gure 1) 7; 8. Rolling of the eosinophils along the endothelial cells is 
the fi rst step in the extravasation process and this reversible adhesion is mainly mediated by 
selectins 9. Three types of selectins are known, L(eukocyte)-, E(ndothelium)-, and P(latelet)-
selectin 9. L-selectin is constitutively expressed on leukocytes, whereas P-selectin is expressed 
on activated platelets. P- and E-selectin are expressed on endothelial cells activated by pro-
infl ammatory cytokines such as IL-1 and tumor necrosis factor 10. The selectins attach to a 
specifi c glycoproteins, such as PSGL-1 (P-Selectin Glycoprotein Ligand-1), ESL-1 (E-Selectin 
Ligand-1), and MadCAM (Mucosal Addressin Cell Adhesion Molecule-1) 11; 12; 13; 14. Activation of 
the rolling cell by chemo-attractants induces fi rm adhesion and subsequent spreading of the 
cell, which are mediated by integrins 15. Integrins are cell-surface receptors responsible for cell 
attachment to extracellular matrices and to other cells, including endothelial cells, by binding to 
their counter ligands, which belong to the immunoglobulin superfamily 16. Next, the cell migrates 
to the site where endothelial cells connect to each other and passes between them to the tissue 
17
. When cells have passed the endothelium, they interact with the extracellular matrix proteins 
such as fi bronectin.
Once eosinophils are present in the tissue, activation can result in cytotoxicity. Eosinophils 
utilise two main cytotoxic mechanisms: degranulation and the respiratory burst (fi gure 2). 
Degranulation occurs through the secretion of granule-associated toxic cationic proteins, 
enzymes and lipid mediators. Three types of granules are recognized at different stages of 
eosinophilic maturation. The primary (coreless) granules are round, uniform and observed 
at the stage of eosinophilic promyelocyte in the bone marrow 18. As eosinophils differentiate, 
the primary granules develop into core-containing specifi c granules 18. Eosinophil Peroxidase 
(EPO), Major Basic Protein (MBP), Eosinophil Cationic Protein (ECP), and Eosinophil-Derived 
Neurotoxin (EDN) are present in both primary and specifi c granules, but their distribution differs 
19
. In primary granules, MBP has a uniform distribution, whereas in specifi c granules MBP has 
a crystalloid core distribution, while the matrix surrounding it contains ECP, EPO, and EDN. 
Exocytosis and piecemeal degranulation represent two functionally different processes by which 
eosinophils release their granule mediators. Piecemeal degranulation provides the possibility of 
a long-lasting and selective release of granule content 20; 21. Eosinophil exocytosis, on the other 
hand, occurs classically as a regulated event in the context of granule-to-granule or granule-
to-plasma membrane fusion and extrusion of nonmembrane-bound granule 22. A third type of 
granule, the lipid body, is a non–membrane-bound, lipid-rich cytoplasmic inclusion. Lipid bodies 
increase in numbers and size in cells associated with infl ammation. They would serve as sites at 
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which the coordinated and regulated enzymatic events involved in arachidonate mobilization and 
oxidative metabolism could occur 23.
During the respiratory burst, the eosinophil produces toxic oxygen metabolites. These reactive 
oxygen species (ROS) are produced by a membrane-bound NADPH-oxidase, which reduces 
molecular oxygen into superoxide. Subsequently, this superoxide can be further converted into 
other ROS species, for example hydrogen peroxide. These oxygen metabolites are cytotoxic 
for micro-organisms and synergize with toxic granule proteins (e.g. EPO) to facilitate microbial 
killing 24; 25.
Apart from being important effector cells, eosinophils can act as pro-infl ammatory cells. They 
have the capacity of producing large amounts of cytokines and chemokines including IL-4, IL-
5, GM-CSF, interferon-γ, TNF-α, RANTES (regulated on activation, normal T-cell expressed 
and secreted), IL-8, and IL-10 26-30.  In addition, several bioactive lipids are formed for example 
platelet activating factor and leukotrienes C4 and B4 31; 32. All these mediators are involved in 
various stages of the infl ammatory response and can act on eosinophils or other infl ammatory 
cells, contributing to ongoing infl ammation. Furthermore, eosinophils are reported to have anti-
infl ammatory properties. They have the ability to release enzymes such as histaminase and 
arylsulfatase, which are recognised to degrade histamine and leukotrienes respectively 33; 34. 
Figure 2. Eosinophil mediated killing. Eosinophils utilize two cytotoxic mechanisms, 
degranulation and the respiratory burst. Degranulation occurs through the secretion of granule-
associated toxic cationic proteins, enzymes and lipid mediators. During the respiratory burst, 
the eosinophil produces toxic oxygen metabolites. These reactive oxygen species (ROS) 
are produced by a membrane-bound NADPH-oxidase, which reduces molecular oxygen into 
superoxide. These two mechanisms synergize in the killing reaction
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The role of eosinophils in diseases
Eosinophils are strongly associated with the defence against infections caused by macro 
parasites, especially helminths 35; 36. Helminth infections cause an increase in the number of 
circulating eosinophils and a massive eosinophil infi ltration can be observed at the site of the 
parasite 37; 38. Eosinophils can bind to the surface of the helminths in vitro, both larval and adult 
forms, thereby damaging the surface of the helminth by release of granule proteins such as MBP 
and ECP or by peroxidation via EPO 39; 40. Oxidative reactions are not essential for the killing, but 
they can clearly enhance the toxic effect of the cationic proteins.
In contrast to this benefi cial role in host defence, eosinophils are also thought to play an important 
role in the pathogenesis of allergic diseases, such as allergic asthma 41; 42. Allergic asthma is 
a complex clinical syndrome characterised by variable airfl ow obstruction, bronchial hyper-
responsiveness and chronic airway infl ammation 43; 44. The acute allergic reaction usually occurs 
within minutes of antigenic challenge and is generally referred to as the early-asthmatic response 
(EAR). The EAR is followed 2 to 6 hours later by the late-asthmatic response (LAR), which 
involves infi ltration of the airways by eosinophils, mononuclear cells, and lymphocytes as well 
as elaboration of TH2 cytokines and chemokines 45; 46. The TH2 cytokines IL-4 and IL-13 regulate 
IgE expression by B-lymphocytes, whereas tumor necrosis factor α, IL-1, and chemokines (e.g., 
IL-8) are responsible for cellular recruitment. IgE secreted by B-lymphocytes binds to high-
affi nity IgE receptors on human mast cells and basophils 47-50. Interaction of allergen with the 
specifi c IgE molecules on the surface of these cells causes cross-linking and triggering of the cell 
receptor with concomitant activation of mast cells and basophils. Together with chronic signals 
by the innate immune system the infl ammation persists. The level of eosinophilic infl ammation 
of the airway in asthmatics correlates with the severity of asthma 43; 51. Eosinophils are believed 
to cause long-term tissue damage when activated to release their granule content of cationic 
proteins, including EPO, EDN, MBP, and ECP. The capacity of these proteins to damage airways 
epithelium has been demonstrated in vitro and in vivo 52-55. In response to allergic stimuli in the 
lung, the eosinophil pool in the bone marrow expands and the number of eosinophils residing in 
the blood and at the site of allergen provocation increases markedly 41; 42.
Hematopoiesis 
The human hematopoietic system of produces about one trillion blood cells each day 56. This 
continuous process involves the sequential commitment of multipotential hematopoietic stem 
cells (HSC) to gradually more-restricted progenitor cells, and fi nally to the functionally distinct 
cells found in peripheral blood: erythrocytes, platelets, neutrophils, eosinophils, monocyte/
macrophages, and lymphocytes. Within the fi rst two stages extensive expansion/proliferation 
of cells occur. Hematopoiesis occurs at distinct anatomic sites during human development 57-
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59
. Embryonic hematopoiesis begins when blood develops from the mesoderm in the yolk sac. 
Defi nitive hematopoiesis is initiated in the fetal liver, and occurs in the bone marrow after birth.
HSC are currently defi ned as single cells that are capable of self-renewal. These cells can also 
differentiate into a defi ned set of committed progenitors 60; 61. They are negative for markers found 
on T cells, B cells, granulocytes, mono/macrophages, erythrocytes, NK cells etc 62. These stem 
cells are very rare, about only one in 10,000 bone marrow cells. Human HSC have been isolated 
from umbilical cord blood, fetal liver, fetal and adult bone marrow, and mobilized peripheral blood 
(MPB) 63; 64. HSC can be divided into long-term repopulating (LT-HSC) and short-term repopulating 
cells (ST-HSC) based on degree of self-renewal 65. Long-term self-renewal is limited to LT-HSC 
in the hematopoietic stem and progenitor pool 66. Despite intensive investigation, the mechanism 
underlying the genetic control of self-renewal and LT-HSC expansion remains undefi ned. All 
leukemias and clonogenic cancer cells have gained (or retained) the properties of self-renewal, 
therefore it is crucial to defi ne the genetic control of the LT-HSC class of stem cells. 
As shown in fi gure 3, downstream of the clonogenic multipotent pool are two developmental 
choices, either myeloid or lymphoid 61; 67; 68. This raises a question: what are the molecular 
mechanisms that dictate the fate of a common precursor to a particular lineage? Over the years, 
several models have been proposed that describe the hematopoietic lineage determination. 
The inductive model suggests active roles for instructive signals in directing stem cells to commit 
to a particular hematopoietic lineage, such as signals provided by lineage-specifi c cytokines 
or stromal cells 69; 70. This is supported by fi ndings that cytokines such as erythropoietin and 
thrombopoietin provoke differentiation by inducing specifi c factors, such as signal transducers 
and activators of transcription (STAT) or cyclin dependent kinase inhibitors 71-76. 
On the other hand the stochastic model describes mechanisms in the pluripotent cell that 
determine their hematopoietic fate and are independent of extracellular signals 77. The role of 
cytokines is merely to provide survival and proliferation signals. This is supported by recent work 
which has shown that introduction of the anti-apoptotic bcl-2 gene into a pluripotent hematopoietic 
cell line, results in multi-lineage differentiation of these cells in the absence of cytokines 78. It is 
also possible that a combination of these two models exist. Stochastic processes determine the 
preferred differentiation patterns, but exposure to a particular cytokine pathway may re-enforce 
or override the selection. 
Granulopoiesis
The development of mature hematopoietic cells from the pluripotent HSC involves a regulated 
progression through lineage commitment, terminal differentiation, and growth arrest. The fi rst 
two lineage progenitors recognized are the common lymphoid progenitor and the common 
myeloid progenitor or granulocyte/erythroid/macrophage/megakaryocyte colony-forming unit 
(GEMM-CFU). Each of these progenitors is a clonal precursor of a limited subset of progeny, 
and has a distinct expressed gene profi le 61; 79; 80. 
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GEMM-CFU can give rise to more lineage-restricted progenitors: the megakaryocyte/erythrocyte 
CFU, the granulocyte/monocyte CFU, and the eosinophil/basophil CFU 81; 82. The presence of 
a common late stage progenitor of eosinophils and basophils was demonstrated by a common 
progenitor in clonal assays, shared content of the major granule proteins and proteoglycans 
and the occurrence of various forms of transition between the two cells types. Under normal 
conditions the clonogenic precursors, the megakaryocyte/erythrocyte CFU, the granulocyte/
monocyte CFU, and the eosinophil/basophil CFU are absolutely lineage restricted and do not 
self-renew upon transplantation 83. These cells are capable to differentiate via their various 
precursor cells into mature blood cells (fi gure 3).
Figure 3. A model for hematopoiesis. Linear model for the differentiation from hematopoietic 
stem cell into the different mature cells, the lineage specifi c cytokines are added to the different 
branches. CLP: common lymphoid progenitor. CMP: common myeloid progenitor. ME-CFU: 
megakaryocyte and erythrocyte progenitor. Eo/B-CFU: eosinophil and basphil progenitor. GM-
CFU: granulocyte and monocyte progenitor. Mega: megakaryocyte. Ery: erythrocyte. Baso: 
basophil. EO: eosinophil. Neutro: neutrophil. Mono: monocyte.
LT-HSC ST-HSC CMP
ME
CFU
GM
CFU
Eo/B
CFU
CLP
Ery
Mega
Baso
EO
Neutro
Mono
IL-7
TPO
EPO
TPO
IL-3 + GM-CSF
IL-5
IL-3
IL-3 +
GM-CSF
G-CSF
M-CSF
IL-5
Chapter 1
16 17
Cytokines in hematopoiesis
The inductive model describes active roles for lineage-specifi c cytokines in directing stem cells 
to commit to a particular hematopoietic lineage (fi gure 3). Cytokines are pleiotropic; they can 
act on different cells and induce a wide range of responses. These multiple biological effects 
can be explained by the range of signalling components and transcription factors present in the 
target cells at the time of stimulation with the cytokine. However, several cytokines can act on 
one target cell to elicit the same response. This can be explained, in part, by the fact that the 
receptors for cytokines share common subunits important for signal transduction 84; 85.
Interleukin-7 (IL-7) is a major factor in stimulating bone marrow stem cells to differentiate 
towards lymphocytes (mostly B cells and T cells). The hormone thrombopoietin, secreted 
by the liver, induces the lineage leading to megakaryocytes and erythrocytes. Erythropoietin 
induces the production and differentiation of erythrocytes. The production of megakaryocytes 
and their fragmentation into platelets is stimulated by thrombopoietin assisted by Interleukin-
11. Interleukin-3 (IL-3) participates in the differentiation of most of the white blood cell lineages 
but plays a particularly prominent role in the formation of basophils. Granulocyte-macrophage 
colony-stimulating factor (GM-CSF), as its name suggests, directs cells down the lineage 
leading to both those cell types. Further differentiation into neutrophils is under the infl uence 
of granulocyte colony-stimulating factor. On the other hand, stimulation of the granulocyte/
macrophage progenitor cells by macrophage colony-stimulating factor induces differentiation 
into monocytes, the precursors of macrophages. 
Certain cytokines appear to be more restricted in their actions than others, both in terms of 
lineage and the stage of differentiation of the responsive cells. Some cytokines promote the 
growth and survival of progenitors and support the development of more than one lineage of 
cells, like IL-3 and GM-CSF. In contrast, other cytokines act primarily on a particular lineage of 
cells, such as granulocyte colony-stimulating factor and erythropoietin.
Cytokine receptors
Cytokines regulate their function through specifi c receptors. Most cytokine receptors consist of 
multiple subunits, one of which is cytokine specifi c. The cytokine specifi c subunits are involved in 
the specifi c binding of ligand, while the common components mediate cytokine activated signal 
transduction pathways and can be shared between several cytokine receptors. The receptors for 
IL-2, IL-4, IL-9, and IL-15 all use the same signal transducing γ chain 86; 87; 88. Therefore, these 
cytokines generally activate similar signal transduction pathways in various cell types.
The receptors for IL-3, IL-5, and GM-CSF each consist of two distinct membrane proteins. The 
α-chain is cytokine-specifi c and binds the ligand with low affi nity, and the common β chain (βc) 
is shared among the receptors 89-93. Although the βc-chain does not bind IL-5 by itself, it forms a 
high affi nity receptor by dimerisation with the β-chain 91; 94. Upon dimerisation, multiple tyrosine 
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residues in the βc become phosphorylated, mainly by members of the Janus kinase (JAK) family 
95; 96
. The phosphorylated receptor provides docking sites for a variety of Src-homology 2 (SH2) 
domain-containing proteins, including STATs (signal transducers and activators of transcription). 
In the last decade many of the signal transduction pathways regulated by the phosphorylated βc 
have been identifi ed, including the PI-3K/PKB and the Ras-ERK pathways 95. 
Although the βc initiates signal transduction events specifi c for this cytokine family, it will not 
distinguish between IL-3, IL-5, and GM-CSF. The cytokine specifi c α-chains on the other 
hand are likely candidates for mediating specifi city in signalling between cytokines of one 
family. Although the intracellular domains of the α-chains are rather short, they play a role in 
signal transduction, since deletion of the cytoplasmic domains abrogates receptor signalling 97. 
Recently mechanisms of transcriptional activation by cytokine-specifi c receptor subunits were 
identifi ed. Syntenin associates with the cytoplasmic tail of the IL-5Rα. Syntenin was found to 
directly associate with the transcription factor Sox4. Association of syntenin with IL-5Rα was 
required for IL-5-mediated activation of Sox4 98. Furthermore, a novel protein GRAP (GM-CSF 
receptor α subunit-associated protein) was identifi ed which binds to GM-CSFα, indicating that it 
may play a role in GM-CSF specifi c signal transduction 99.
Expression of the cytokine specifi c β-chain may be critical to the entry of multipotential myeloid 
progenitors into a particular hematopoietic developmental program.
IL-5 in eosinophil differentiation 
Interleukin-5 is produced in lymphocytes, mast cells, eosinophils, and airway smooth muscle 
and epithelial cells 100; 101. Biologically active interleukin-5 is a disulfi de-linked homodimer that is 
held together by the highly conserved cysteine residues that orientates the monomers in an anti 
parallel arrangement 102; 103; 103. IL-5 promotes growth and differentiation to mature eosinophils 
in the bone marrow 104; 105. Other studies showed that CD34+ cells cultured in the presence of 
IL-5 were committed to the eosinophil lineage and were capable of forming eosinophil colonies 
104; 106
. The role of IL-5 and eosinophils is best studied in relation to allergic asthma. Beside the 
increased levels of IL-5 in peripheral blood of asthmatic patients, also Eo/B-progenitors are 
elevated in blood of asthmatics after allergen challenge 107-110.
Transgenic mice, in which IL-5 is constitutively expressed in T-cells, show a profound and 
lifelong eosinophilia, with large numbers of eosinophils in the blood, spleen and bone marrow 
111
. In mice with an inactive IL-5 gene, lung eosinophilia was absent and very little infl ammation 
and lung damage was observed after allergen challenge, unless the system is reconstituted with 
IL-5 112. Furthermore, anti-IL-5 treatment prevents pulmonary eosinophilia and bronchohypere
sponsiveness in animal models 113; 114, lasting months after a single injection; these effects are 
consistent with a systemic; perhaps bone marrow, suppression induced by IL-5. Leckie et al. 
studied the effect of a humanized anti-IL-5 antibody in allergic asthmatics and showed a clear 
reduction in blood eosinophils 115. 
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Other factors involved in hematopoiesis
Under normal conditions, hematopoiesis takes place within the bone marrow microenvironment. 
It has been shown that microenvironment where the stem cells reside play critical roles in the 
determination of their self-renewal or differentiation choices. HSC and the progenitors interact 
relatively specifi cally with cell and extracellular matrix ligands present in the bone marrow 116-
118
. These adhesive interactions are responsible for the retention of hematopoietic cells in the 
marrow. Like hematopoietic cells, hematopoietic cytokines bind to some specifi c extracellular 
matrix components, and stromal cells can express certain cytokines on their surface 119; 120; 121. 
Selective adhesion of progenitors and cytokines to extracellular matrix components or stromal 
cells then results in the co-localisation of progenitors at a specifi c stage of differentiation with a 
specifi c array of cytokines, in so-termed niches 122; 123.
There is also mounting evidence that contact interactions per se between progenitors and marrow 
stromal ligands play an important role in the regulation of the hematopoietic process 124; 125; 126. 
Adhesive interactions themselves may serve as growth or survival signals or adhesion itself 
may modulate cytokine- or growth factor-dependent signals. More than 20 different adhesion 
receptors have been identifi ed on hematopoietic progenitors 127; 128. These include members of 
the integrin family responsible for adhesion to ECM components (fi bronectin, collagen, laminin, 
or thrombospondin) or adhesion ligands expressed by other cells 129-131. 
Integrins are cell adhesion molecules that can transmit signals between progenitors and bone 
marrow stromal cells. They are heterodimeric transmembrane glycoproteins, composed of non-
covalently associated α and β subunits 16; 132. Differentiation of β1 knockout precursors is normal 
in vitro. However, these cells accumulate in the blood in vivo 133. This indicates that β1 integrins 
are essential for the adhesion of HSC to the vessel wall, and thereby the homing to the bone 
marrow, but not for their development. Moreover, β1-integrins and their ligands are ubiquitously 
expressed and β1-integrins are not suffi cient for the rather exclusive progenitor-marrow 
interactions. Thus, another receptor(s) must be responsible for the specifi c stem cell-marrow 
interactions. A candidate is the α4 subunit, which can associate with β1 and β7 integrins and is 
important for the differentiation of erythroid, myeloid and B cell progenitors 134.
Transcription factors 
In the stochastic model default mechanisms in the pluripotent cell determine their hematopoietic 
fate independently of specifi c extracellular signals. Transcription factors are a possible intrinsic 
mechanism by which hematopoietic determination occurs. Transcription factors are sequence-
specifi c DNA-binding proteins with a variety of functions that include the initiation of DNA 
replication and the control of gene transcription 135. Transcription factors are classifi ed according 
to the three-dimensional structure of their DNA-binding motifs. Regulation of transcription factor 
activity occurs through their binding to DNA sequences, the relative concentration of particular 
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transcription factors within the cell, post-translational modifi cation (phosphorylation and 
acetylation) and the presence of co-factors 135. 
The pattern of gene expression within a cell is established by cell-type specifi c transcription 
factors that mediate the net effect of the variety of proliferation and differentiation signals that 
impinge on it. Therefore, it is interesting to understand more about the role of transcription 
factors during differentiation. Lineage-restricted transcription factors provide a valuable starting 
point in searching for the molecular mechanisms of cell differentiation. Gene-knockout studies 
in mice have provided clues of the essential roles of transcription factors during discrete stages 
of hematopoiesis. However, in targeted gene disruption of the mouse it is only possible to 
investigate the fi rst action of a factor in a cascade. Conditional knockouts and analysis of mice 
that are defi cient in more than one transcription factor will be necessary. 
In the last decade it has become clear that the expression of lineage specifi c genes is regulated 
by the combinatorial association of transcription factors present in the early and committed 
progenitors, and in more differentiated cells (For review see 136; 137). Transcription factors 
regulating expression of lineage specifi c genes are not exclusively expressed in that particular 
lineage. However, the overlapping expression patterns and the combinatorial action of these 
factors may provide the specifi city to regulate transcription of lineage specifi c genes. Many 
lineage specifi c genes have binding sites for multiple transcription factors. There are many 
examples where transcription factors function in concert to upregulate gene expression. For 
example, AML-1, its binding partner CBFβ, or C/EBP α each not signifi cantly stimulate the 
myeloid specifi c M-CSF receptor promoter activity. However, the simultaneous expression of all 
three proteins was shown to increase the promoter activity 90-fold 138. 
Another level of regulation of differentiation is by graded concentrations of transcription factors. 
Low PU.1 expression in progenitors specifi cally induces B-cell development, whereas high PU.1 
levels suppress the B-cell fate and instead promote macrophage differentiation 139.
Recently, it became clear that besides these positive ways of activation of a unique program of 
gene expression, lineage-specifi c transcription factors simultaneously exert inhibitory effects on 
alternate lineage gene programs by directly antagonizing the action of opposing transcription 
factors 140-142. This means that a particular cell type will express a subset of transcription factors 
characteristic for the lineage, and these will positively regulate genes specifi cally expressed 
in the lineage. On another level these transcription factors specifi c for one lineage will repress 
genes of another lineage. This cross-antagonism of different lineage-specifi c transcription 
factors has been shown for PU.1 and GATA-1 (see fi gure 5). 
Chapter 1
20 21
Transcription factors in hematopoiesis 
Different transcription factors have been implicated in the cell-fate decisions made at different 
time-points during hematopoiesis. Two of the transcription factors known to be essential for 
defi nitive hematopoiesis are c-Myb and AML1 (CBF-α). Both factors were fi rst identifi ed as 
oncoproteins, playing a role in a variety of different leukemias 143-145. The core binding factors 
(CBF) are a small family of transcription factors comprising a DNA binding CBFα subunit and a 
non-DNA binding CBFβ subunit 146. One gene encoding a CBFα subunit, RUNX1 (also known as 
AML1, CBFαA2, and PEBPA2A), and the gene encoding CBFβ are essential for hematopoiesis 
and are frequently mutated in human leukemias 145; 147. The importance of AML1 in hematopoiesis 
has been shown by the phenotype of AML1 and CBFβ knockout mice. Both mice lack defi nitive 
hematopoiesis and die in utero, and embryonic stem cells from these null mice are unable to 
contribute to defi nitive hematopoiesis in chimeric mice. 148-152. These fi ndings demonstrate that 
AML1/CBFβ is essential for defi nitive hematopoiesis. However, its exact role in regulating 
the proliferation, self-renewal, and commitment of hematopoietic cells remains unknown. 
The CBF complex regulates the expression of various genes, including granulocyte-colony-
stimulating factor (G-CSF) receptor, macrophage-colony-stimulating factor (M-CSF) receptor, 
myeloperoxidase, interleukin-3, and T-cell-receptor β gene 149-151.
c-Myb is highly expressed in immature hematopoietic cells and is down regulated during 
terminal differentiation of these cells 153; 154. Knockout of the c-Myb gene results in embryonic 
lethality with a failure of hematopoiesis in fetal liver 155. However, ectopic expression of c-
Myb in the promyelocytic cell line 32Dcl3 permits G-CSF induction of primary granule protein 
myeloperoxidase although there is no further evidence of involvement in terminal differentiation 
156
. This is in agreement with the idea that c-Myb stimulates cell proliferation and that cell cycle 
arrest is required for the terminal differentiation.
An important decision point in hematopoiesis for the common myeloid progenitor is the choice 
between the erythrocyte/megakaryocyte, the eosinophil/basophil, and the neutrophil/monocyte 
lineage. Two important transcription factors at this point are GATA-1 and PU.1 141; 142; 157. The 
GATA family of transcription factors contain an N-terminal activation domain and two conserved 
zinc fi ngers: the C-fi nger is capable of binding to DNA, whereas the N-fi nger stabilizes DNA 
binding. In addition to contacting DNA, the zinc-fi ngers also interact with another transcriptional 
co-factor, called Friend of GATA-1 (FOG-1) 158. Within hematopoietic cells, expression of GATA-
1 is limited to the erythroid, megakaryocyte, eosinophil, and basophil lineages and progenitors 
159
. Targeted disruption of the mouse GATA-1 gene has provided strong evidence for its role as a 
key regulator of erythrocyte and megakaryocyte differentiation. Many erythroid-expressed genes 
contain GATA-motif sequences. GATA-1 is important in erythropoiesis and megakaryopoiesis 
and direct interaction with FOG-1 is required for terminal erythroid and megakaryocyte 
maturation. Ectopic expression of GATA-1 in myeloid cell lines leads to trans-differentiation into 
eosinophils (at intermediate GATA-1 levels) or de-differentiation into multiple progenitors (at high 
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GATA-1 levels) 160; 161. This indicates that down-regulation of GATA-1 is a pre-requisite for the 
proper execution of the gene expression program.
PU.1 is a member of the Ets transcription factor family, possessing a glutamine-rich trans-
activating domain at its N-terminus, the Ets domain and a C-terminal DNA binding domain 162. Ets 
proteins bind to DNA as monomers and mediate protein-protein interactions that are only stable 
in the presence of DNA. DNA binding introduces conformational changes in PU.1 and exposes 
protein interaction domains. PU.1 is the most abundant Ets family member expressed in myeloid 
cells. Since almost all myeloid promoters have a functional PU.1 site close to the transcriptional 
start site, PU.1 is an important regulator of myeloid gene expression. Mice lacking PU.1 die one 
to three days before their expected birth 163. The principal hematopoietic effects are absence of 
monocytes, neutrophils, eosinophils, and B and T lymphocytes. 
Figure 4. Antagonism between PU.1 and GATA-1. A Interaction between PU.1 and the co-
factor c-Jun is required for expression of PU.1 target genes. B GATA-1 blocks the interaction 
between c-Jun and PU.1 by binding to PU.1. C Activation of GATA-1 target genes requires the 
binding of GATA-1 with DNA. D PU.1 binds to the DNA-binding domain of GATA-1, thereby 
blocking the activation of GATA-1 target genes.
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There is also cross-antagonism between the lineage specifi c transcription factors GATA-1 and 
PU.1. Both transcription factors are expressed at low levels in multipotential precursor cells 164; 
165
. Under direction of signals that are as yet undefi ned, GATA-1 or PU.1 is up regulated. Once 
GATA-1 is up regulated this leads to transactivation of its own promoter and stimulation of the 
erythropoietin receptor. However, when PU.1 is activated in a progenitor, this leads to stimulation 
of PU.1 through an auto-regulatory loop and triggers the expression of M-GSF, important for 
myeloid development. Recent studies have shown functionally important protein-protein 
interactions involving the lineage decision of the common myeloid progenitor 140-142. GATA-1 
inhibits PU.1 transactivation of PU.1 target genes by blocking the binding of the PU.1 co-activator 
c-Jun to the Ets domain of PU.1. The N-terminal region of PU.1 blocks GATA-1 function by 
binding to the GATA-1 C-fi nger and inhibiting GATA-1 binding to DNA (see fi gure 4).
C/EBP family
The CCAAT/enhancer binding protein (C/EBP) consists of six family members: α, β, γ, δ, ε, and 
ζ, which are part of a family of basic leucine zipper transcription factors. All C/EBP isoforms 
share substantial sequence identity (>90%) in the carboxy-terminal 55-65 amino acids residues, 
which contains the bZIP domain 166-168. The leucine zipper consists of four or fi ve repetitive 
leucine residues spaced every seven amino acids that result in an α helical amphipatic structure 
with hydrophobic and hydrophilic faces on each site of the helix. The leucine zipper is directly 
involved in homo- and heterodimerisation by a parallel coil-coil interaction and dimerisation is a 
pre-requisite for DNA-binding 167; 168. Just amino terminal to the zipper is a basic region that is 
highly positively charged and directly interacts with DNA. C/EBP dimers bind to the consensus 
target site TTNNCCAAC. The promoters of many myeloid specifi c genes contain the C/EBP 
consensus-binding site, including granule proteins and cytokine promoters and are targets for 
transcriptional regulation by C/EBP family members. In contrast to the bZIP domain, the N-
termini of the C/EBP proteins are quite divergent (<20% sequence identity) except for three short 
sub-regions that are conserved in most members 102. These sub-regions represent the activation 
domains that interact with components of the basal transcription machinery and stimulate 
transcription 169-173.
The founding member of this family, C/EBPα was fi rst identifi ed to be highly expressed in liver 
and adipose tissue 174; 175. C/EBPβ (NF-IL-6, LAP, IL6-DBP, NR-M) was originally described as 
a nuclear factor that binds the IL-1 responsive element in the IL-6 promoter 176; 177. Constitutive 
expression of C/EBPδ  is detected in intestines, adipose, and lung, however, high levels of 
expression are found in all tissues following LPS stimulation 178-180. 
Coordinate expression of specifi c C/EBP isoforms is essential for normal hepatic synthetic activity 
and response to injury, C/EBPα is the predominant nuclear signal regulating terminal hepatocyte 
differentiation and function. Elimination of C/EBPα in mouse knockout models results in profound 
derangement of liver structure and function and death from hypoglycaemia within eight hours of 
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birth 181; 182. Low level expression of phosphoenolpyruvate carboxykinase and perinatal lethality is 
also seen in a subset of C/EBPβ knockout mice, suggesting involvement of the C/EBPβ isoform 
in gluconeogenic pathways 183.
Mice defi cient for both C/EBPβ and C/EBPδ die perinatally, similar to C/EBPα knockout mice 
184
. C/EBPβ/δ double knockout mice did not accumulate lipid droplets in brown adipose tissue 
and had signifi cantly reduced epidydimal fat pads in surviving adults 184. Despite these defects, 
C/EBPα and PPARγ (peroxisome proliferator-activated receptor) expression was normal, 
suggesting that C/EBPα and PPARγ are not suffi cient for adipocyte differentiation in the absence 
of C/EBPβ and C/EBP δ 184. 
C/EBPγ is ubiquitously expressed and the highest levels are found in non-differentiated, 
progenitor cells 185-187. C/EBP ζ (also named CHOP) was fi rst isolated as growth arrest and DNA-
damage inducible gene 153 (gadd153) and is, like C/EBP γ, ubiquitously expressed 188-190. C/
EBPγ contains the basic and leucine zipper motifs that characterize the C/EBP family, but lacks 
the transcriptional activation domain present in the other family members 187. C/EBPζ possesses 
a leucine zipper dimerisation domain and a DNA binding region, however, the presence of two 
prolines in the DNA binding region disrupts its helical structure and prevents heterodimer binding 
to C/EBP enhancer sequences. Therefore C/EBPζ and C/EBPγ function as inhibitors of C/EBP 
transcriptional activation 190.
C/EBP transcription factors demonstrate a unique temporal pattern of isoform expression in 
the myeloid lineage 191. Within the hematopoietic system, C/EBPα expression is restricted to 
the neutrophil, monocyte, and eosinophil lineage. C/EBPα is highly expressed in proliferating 
myelomonocytic cells upon induction of differentiation and maintained during eosinophil and 
neutrophil differentiation. C/EBPβ levels are low in immature myeloid cells, increase after 
stimulation with IL-6, LPS, and IL-1, and are highest in macrophages and neutrophils 191; 192. 
C/EBP,ε the most recently cloned member of the C/EBP family, is only expressed in myeloid 
lineages, with some low but detectable expression in the lymphoblastic cell line MOLT4 and 
the ovaries 193; 194. C/EBP isoforms are not detected in either erythroid or lymphoid cells. The 
formation of tissue-specifi c combinations of C/EBP homodimers and heterodimers may allow 
this family of transcription factors to regulate different sets of genes in adipocytes, hepatocytes, 
and myeloid cells.
In the C/EBP α knockout mice, immature myeloid cells were found to be present in the 
peripheral blood in the absence of mature neutrophils or eosinophils 195. Development of other 
hematopoietic lineages, including monocytes and macrophages was not affected. These fi ndings 
demonstrate that disruption of C/EBPα produces a selective block in the development of mature 
granulocytes. Co expression of C/EBPα with other myeloid transcription factors synergistically 
activates myeloid-specifi c promoters.
The low basal DNA-binding activity of C/EBPβ is markedly increased by infl ammatory stimuli, 
which induce phosphorylation and translocation to the nucleus, where it can activate multiple 
cytokine gene promoters 177; 196; 197. Studies of mice with a targeted disruption of C/EBPβ gene 
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have demonstrated the importance of C/EBPβ for macrophage functions related to bacterial 
killing and tumor cytotoxicity. Nevertheless myeloid cell development was not adversely affected, 
consistent with a role of C/EBPβ in cytokine activation rather than lineage development 198; 199. 
C/EBPβ deletion may be compensated by the presence of other C/EBP family members during 
early myelopoiesis. C/EBPβ is thought to play a role in the regulation of the eosinophil-specifi c 
MBP promoter. However in knockout mice there is no indication that it is involved in the regulation 
of eosinophil differentiation 200. C/EBPδ defi c ient mice show no phenotypic abnormalities in 
hematopoietic lineages.
In contrast to C/EBPα acting early in myeloid differentiation, C/EBPε is involved more in terminal 
differentiation 166; 193; 201. C/EBPε nullizygous offspring are normal at birth and fertile. However, they 
fail to produce normal neutrophils or eosinophils 202. Median survival of C/EBPε-defi cient mice 
is 50 to 75 days with the usual cause of death due to opportunistic infection with Pseudomonas 
aeruginosa with concomitant tissue destruction 202. Additionally, peripheral blood white cell 
differentials in young mice (two weeks of age or less) show only a slight increase in less mature 
myeloid cells in knockout animals compared with wild-type mice 202. Conversely, older mice 
(three to four months of age) display a pronounced increase in immature myeloid forms in both 
their peripheral blood and bone marrow 202. Although C/EBPε defi c iency blocks the maturation of 
granulocytic lineages, there is no effect on both erythropoiesis and lymphopoiesis.
Transcription factors in eosinophil differentiation
Work by Graf and Nerlov has contributed considerably to understanding the role of transcription 
factors in eosinophilopoiesis. Using a model system they focused on the differentiation of avian 
multipotent hematopoietic progenitors (aMEPs) and have demonstrated that a complete down-
regulation of GATA-1 causes MEPs to differentiate into the neutrophil/monocyte lineage. In 
contrast, intermediate levels correlate with the formation of eosinophils and high levels with that 
of thromboblasts and erythroblasts 160. The stabilization of GATA-1 expression at an intermediate 
level is likely to be instrumental in the decision of a multipotent progenitor to choose the eosinophil 
over the neutrophil/monocyte lineage.
They also showed that both the α and β isoforms of C/EBP are able to induce eosinophil lineage 
commitment of aMEPs. C/EBP can regulate genes involved in eosinophil lineage commitment 
independently of its transactivation function. They showed that all C/EBP proteins capable 
of DNA-binding promote eosinophil lineage commitment, whereas only those with an intact 
transactivation domain supported terminal differentiation 203. The results of the C/EBPα and 
C/EBPε knockout mice and the C/EBP induced eosinophil differentiation provide a strong 
indication for an important role of C/EBP in eosinophil lineage commitment. Taken together, the 
forced expression of C/EBPs in aMEPs and of GATA-1 in myeloid cells both lead to eosinophil 
differentiation 160; 203. Therefore, C/EBP and an intermediate level of GATA-1 are likely to be 
suffi cient to specify the eosinophil lineage. 
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FOG has been shown to play an essential role in the maturation of erythroid cells and in the 
early development of the thrombocytic lineage 158. FOG is highly expressed in multipotent 
hematopoietic progenitors, but not in their derived myeloid and eosinophil cells 140; 158; 200. Recent 
data showed that ectopic expression of FOG in an eosinophilic cell line led to down regulation of 
eosinophil specifi c markers and up regulation of MEP markers, indicating that FOG is a repressor 
of the eosinophil lineage. C/EBP-mediated down-regulation of FOG is a critical step in eosinophil 
lineage commitment, indicating that loss of FOG expression is a pre-requisite for eosinophil 
gene expression. Maintenance of a multipotent state in hematopoiesis is achieved through 
cooperation between FOG and GATA-1. FOG repressed the expression of an avian eosinophilic 
marker, EOS47, in a GATA-1 dependent manner. Taken together, C/EBP repress transcription 
of the FOG gene, whereas FOG acts as a co-repressor with GATA-1 to inhibit transcription of 
C/EBP target genes (see fi gure 5).
Figure 5. Antagonism between C/EBP β and FOG. C/EBPβ represses FOG expression at the 
transcriptional level. It is not known whether this occurs by a direct mechanism or through C/
EBPβ target genes. FOG acts as a transcriptional co-repressor of gene activity of C/EBPβ target 
genes through protein-protein interaction with GATA-1.
EOS47C/EBP PU.1 GATA-1
FOGC/EBP
Transcriptional
Protein-protein
interaction
Antagonism between C/EBP and FOG
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Scope of this thesis
Hematopoiesis is the coordinated production of mature blood cells from a common stem cell via 
different stages of commitment and differentiation. The development of the different branches is 
regulated by transcription factors, cytokines and growth factors. Factors regulating cell-specifi c 
gene expression are also important in the control of cell differentiation. The development of 
eosinophils is regulated by transcription factors, cytokines, and growth factors. 
Research questions
How is the expression of eosinophil specifi c proteins regulated?
In chapter 2 the regulation of the eosinophil specifi c granule protein EDN is analyzed. Chapter 
3 and 4 describe the gene regulation of both chains of the IL-5 receptor of which the IL-5Rα is 
eosinophil-specifi c and the shared β-chain is expressed in all myeloid cell types. 
What is the role of C/EBP proteins on granulocyte differentiation?
The effect of a dominant-negative variant of C/EBP proteins in the differentiation CD34+ cells 
derived from human umbilical cord blood towards eosinophils is described (Chapter 5). In chapter 
6 the expression of C/EBPε on G-CSF induced granulocytic differentiation is investigated.
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Abstract
The eosinophil-derived neurotoxin (EDN), a member of the mammalian ribonuclease family, is 
found in the large specifi c granules of human eosinophilic leukocytes. We have investigated 
the role of the C/EBP transcription factor family in the regulation of EDN promoter activity. Here 
we show that the C/EBP family is involved in intrinsic regulation of EDN promoter activity. We 
have identifi ed a C/EBP binding site located at –124 in the proximal promoter of the EDN gene. 
Mutation of this C/EBP site results in a decrease of promoter activity in HL-60-eos cells as well 
as in eosinophils differentiated in vitro from CD34+ cells. Different C/EBP proteins are able to bind 
to the C/EBP site as shown by gel shift assay. Our results indicate the importance of the C/EBP 
family in the regulation of the EDN gene in eosinophils.
Introduction
Eosinophils play an important role in the protection against parasites, and are also involved in 
the pathogenesis of allergic diseases, such as allergic asthma and atopic dermatitis 1, 2. Parasite 
killing and tissue damage found in allergic lesions are both linked to production of toxic oxygen 
metabolites and to the release of eosinophil granule proteins by degranulation or exocytosis 2-4. 
Eosinophil-derived cytotoxic proteins include major basic protein (MBP), eosinophil peroxidase 
(EPO), eosinophil cationic protein (ECP), and eosinophil derived neurotoxin (EDN) 1,5.
EDN is localized in the granule matrix of human eosinophils and possesses neurotoxic, 
helmintoxic, and ribonucleolytic activities 6. EDN is synthesized as a pre-protein of 161 amino 
acids including a 27 amino acid signal peptide, which is processed to form the mature protein 7-10. 
The EDN gene consists of two exons separated by a single intron. The second exon contains the 
complete coding sequence and 3’-untranslated sequences. These structural features are shared 
with other genes of the RNAse gene superfamily, such as ECP. EDN mRNA can be detected 
in the RNA from hypodense eosinophils 9 and during the pro-myelocytic stage of eosinophil 
development as judged by in vitro differentiation of cord blood mononuclear cells 11. Similarly, 
EDN mRNA expression can be detected in the pro-myelocytic HL-60 cell line when it is induced 
to differentiate with interleukin-5 (IL-5) or butyric acid (BA) 9,12,13.
Previously it was shown that optimal expression of EDN in HL-60 cells is dependent on the 
interaction of the proximal promoter sequences and the intron 12. The promoter and the fi rst intron 
contain multiple consensus transcription factor-binding sites. Recently, it was shown that the 
nuclear factor of activated T cells (NF-AT) site plays an important role in the activity of the intronic 
enhancer in undifferentiated HL-60 cells 14, while the intronic PU.1 site is involved in the regulation 
of the gene in the eosinophil-differentiated HL-60-eos cells 13. Over the last years several myeloid-
specifi c genes and their regulatory sequences were characterized. A number of transcription 
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factor families have been shown to be important for the transcription of myeloid specifi c genes, 
including the C/EBP family, the Ets family and cMyb 15-17.Proteins of the rapidly expanding C/EBP 
family belong to the basic domain/leucine zipper class of transcription factors, which bind to DNA 
as homo- and heterodimers with family members or unrelated transcription factors (reviewed in 
18). C/EBPα was initially identifi ed in liver and adipose tissue, where it was found to be important 
for terminal differentiation 19, 20. More recently, it was shown C/EBPα was also expressed in 
early myeloid cells and was involved in the regulation of a number of granulocyte-specifi c genes 
16,21,22
.Mice defi cient in C/EBPα display an early block in the maturation of granulocytes 23. Both 
C/EBPβ and C/EBPδ play a role in the mediation of the infl ammatory response 24, 25. C/EBPγ is 
ubiquitously expressed with highest levels found in non-differentiated progenitor cells. C/EBPγ 
lacks transcriptional activation elements, suggesting a dominant negative regulation of C/EBP 
transactivation in undifferentiated cells 26, 27. C/EBPε is essential for terminal differentiation and 
functional maturation of committed granulocyte progenitor cells 28, 29.
In the present study, we have investigated the role of C/EBP in the regulation of the EDN 
gene during eosinophilic differentiation. Our results demonstrate that C/EBP is involved in 
the regulation of EDN transcription by binding to a site in the upstream promoter. Mutation of 
this C/EBP site strongly decreases the activity of the EDN promoter in HL-60-eos as well as in 
eosinophils differentiated in vitro from CD34+ progenitors.
Materials and Methods
Cell culture, reagents, and antibodies
HL-60 cells, a promyelocytic leukemia cell line, were cultured in RPMI 1640 (Life Technologies, 
Breda, The Netherlands.) supplemented with 8% fetal calf serum, (FCS, Hyclone), 100 U/
ml penicillin (Life Technologies), 100 µg/ml streptomycin (Life Technologies) and 50µM β-
mercaptoethanol. HL-60 7.7 cells were generated by culturing HL-60 cells for two months at 
pH 7.7 in RPMI containing 25 mmol/L N-[2-Hydroxyethyl]piperazine-N’-3-propane-sulfonic acid 
(EPPS; Sigma, St Louis, MO). To further differentiate HL-60 7.7 cells, butyric acid (0.5mmol/L; 
Sigma) was added 4 to 6 days (HL-60-eos cells). 
CD34+ cells were isolated from cord blood and differentiated as described by Caldenhoven et al. 
30
. In short, mononuclear cells (MNC) were obtained by centrifugation of the blood on a Ficoll-
Hypaque gradient (density 1.077 g/ml). MNC cells were incubated with CD34+ antibody and 
magnetic beads, prior to positive selection on a column which was placed in a magnetic fi eld. Cells 
were cultured in Iscove’s modifi ed Dulbecco medium (IMDM; Life Technologies) supplemented 
with 10% FCS, SCF (100 ng/ml), FLT-3 ligand (100 ng/ml), IL-3 (0.1nmol/l), GM-CSF (0.1nmol/
l), and IL-5 (0.1nmol/l). After three days, cells were cultured in IMDM supplemented with 10% 
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FCS, IL-3 and IL-5. From day 21, IL-3 was also omitted from the media. Viability remained >95% 
throughout the 28 day experiment.
COS-1 cells were cultured in Dulbecco’s modifi ed Eagle medium (DMEM; Life Technologies) 
supplemented with 8% heat inactivated fetal calf serum (FCS; Life Technologies), 100 U/ml 
penicillin (Life Technologies), and 100 µg/ml streptomycin (Life Technologies).
The following antibodies were used in this study: anti-C/EBPα (rabbit polyclonal IgG 14aa, sc-
061X; Santa Cruz), anti-C/EBPβ (rabbit polyclonal IgG C-19, sc-150X; Santa Cruz), anti-C/EBPδ 
(rabbit polyclonal IgG M-17, sc-636X; Santa Cruz) anti-C/EBPε (rabbit polyclonal IgG C-22, sc-
158X; Santa Cruz) and C/EBPβ ∆198 (rabbit polyclonal IgG ∆198, sc-746X; Santa Cruz). 
Synthetic oligonucleotides and plasmid construction
The EDN promoter/intron (-300 to +298, GENBANK X16546) was cloned by PCR using human 
genomic DNA 13. The amplifi ed fragment was then sequenced and cloned into the promoterless 
CAT reporter plasmid pBLCAT3. Deletion constructs were generated by PCR and cloned into 
pBLCAT3.Transcription factor binding sites were identifi ed using the TFSEARCH program (http:
//pdap1.trc.rwcp.or.jp/research/db/TFSEARCH.html). 
The following oligonucleotides were used in this study: for site directed mutagenesis ∆-144: 
TCCTTTTTATTCCATGCCATGCCTTGGCTGAG; ∆-124: AGTCCACACGTGATATCATCC
TTTT T; ∆+163: CTGCAAAGACTGACGCGTCTCCTAAGC; for bandshift analysis (only the 
upper strands are shown): -124: AGCTTATGATTGCACAAGTG; ∆-124: AGCTTATGATAT 
CACGTGTG; somatostatin CRE 31. Site-directed mutagenesis was performed as described 
previously 32. Human C/EBPα (a kind gift from Dr. G.W.M. Swart), human C/EBPβ (a kind gift 
from Prof. S. Akira), human C/EBPγ (cloned by PCR from HL-60 cDNA), rat C/EBPδ (a kind gift 
from Prof. S.L. McKnight), human C/EBPε (cloned by PCR from HL-60 cDNA), and DN/C/EBP (a 
kind gift from Dr C. Nerlov) were cloned into the expression vector pLNCX (Clontech).
Transient transfection and CAT assay 
For transfection experiments, COS-1 cells were cultured in six-well dishes (Nunc, Naperville, IL), 
and 3 hrs later the cells were transfected with 6-8 µg supercoiled DNA as described previously 
33
. Following 16-20 hrs exposure to the calcium-phosphate precipitate, medium was refreshed. 
Cells were harvested for CAT assays 24 hrs later. Transfection of HL-60-eos cells and in vitro 
differentiated eosinophils was performed by electroporation at 300V and 960µF (107 cells, 20 µg 
supercoiled plasmid DNA). Two days after transfection cells were harvested for CAT assays. 
CAT assays were performed as described previously 34. CMV-LacZ co-transfection and β-
galactosidase assays were used to correct for variations in transfection effi ciency.
C/EBP regulates the promoter of the EDN gene in human eosinophil cells
Chapter 2
42
Gel Retardation Assay 
Nuclear extracts were prepared from the HL-60-eos line following a previously described 
procedure 35. Oligonucleotides were labeled by fi lling in the cohesive ends with [α32P] dCTP 
using Klenow fragment of DNA polymerase I (Life Technologies, Inc.). Gel retardation assays 
were carried out according to published procedures with slight modifi cations 36. Briefl y, nuclear 
extracts were incubated in a total volume of 20 µl, containing 10mM HEPES-KOH pH 7.9, 
50mM KCl, 5mM MgCl2, 1mM EDTA, 10% (v/v) glycerol, 5mM DDT, 20 µg BSA, 2 µg poly 
dI-dC (Pharmacia Biotech. Inc.) and 1 ng of a [α-32P]-labeled EDN –124 oligonucleotide for 20 
minutes at room temperature. In competition experiments, indicated molar excess of unlabeled 
oligonucleotide was added simultaneously with the [α-32P]-labeled oligonucleotide. For supershift 
analysis, nuclear extracts were pre-incubated with antibodies against C/EBPs for 30 minutes 
on ice before the addition of [α-32P]-labeled oligonucleotide. Protein-DNA complexes were then 
separated on 5% non-denaturing polyacrylamide gels and visualized by autoradiography.
Results
It was previously shown that EDN transcription is dependent on sequences located upstream 
of the fi rst exon as well as in the fi rst intron 12, 13. Several sites in the intron have been reported 
to be important for gene regulation. So far there are no sites in the 5’ upstream region identifi ed 
to play a role in the regulation of EDN. To investigate the role of C/EBP proteins in the 
regulation of the EDN gene we co-transfected HL-60-eos cells with an EDN promoter/intron 
CAT reporter construct and C/EBPγ or a dominant negative form of C/EBP. C/EBPγ lacks 
transcriptional activation elements, and therefore acts as a dominant negative regulator of C/
EBP transactivation. The dominant negative C/EBP (DN/C/EBP) can dimerise with all C/EBP 
family members, but is mutated in the DNA binding domain and therefore unable to bind to DNA. 
Figure 1A shows that co-transfection of C/EBPγ reduces EDN promoter activity with 70%, while 
DN/C/EBP reduces promoter activity with 90%. These results strongly suggest a role for C/EBP 
proteins in the regulation of EDN transcription in HL-60-eos cells.
To examine if the EDN promoter/intron can also be activated by C/EBP proteins in other cell 
systems, we co-transfected different C/EBP family members with the EDN promoter/intron in 
COS cells. As shown in fi gure 1B, both C/EBPα and -δ greatly increase CAT activity, whereas C/
EBPβ and ε increase the activity of the EDN promoter to a lesser extent. These results show that 
the activity of the EDN promoter can be enhanced by C/EBP family members and that C/EBPα 
and -δ are the most potent inducers of EDN transcription.
Computer-assisted analysis of the EDN promoter indicates the presence of three potential C/EBP 
binding sites centered around -144, -124, and +163. To determine which of the C/EBP sites are 
involved in the regulation of the EDN promoter, we constructed a number of deletion constructs, 
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which are schematically shown in fi gure 2A. The responsiveness of these constructs to C/EBP 
co-transfection was then tested in COS cells. Figure 2B shows there was a slight reduction 
of C/EBP induced promoter activity when C/EBP -144 was deleted (-128 - +173). However, 
deletion of the regions containing C/EBP –124 (-95 - +173) or C/EBP +163 (-167 - +123) leads 
to a stronger decrease of promoter/intron activity in C/EBP transfected cells. These results show 
that the putative C/EBP binding sites C/EBP -124 and C/EBP +163 might be involved in the 
regulation of the EDN promoter.
To investigate if the putative C/EBP binding sites are also involved in eosinophilic cells 
containing endogenous C/EBP proteins, we transfected the deletion constructs in HL-60-eos 
cells (fi g. 3A). Deletion of the region –167 to –128, containing the putative C/EBP –144 binding 
site, slightly reduces promoter/intron activity, whereas deletion of the regions -128 to –95 or +123 
to +173, which contains either the C/EBP –124 or the C/EBP +163 binding site show a signifi cant 
decrease in promoter/intron activity. However, the deletion construct –95 - +173, containing only 
C/EBP +163 shows a low activity. These results suggest that C/EBP family members play an 
important role in EDN promoter regulation, and that C/EBP –124 binding site seems to be more 
important than the C/EBP +163 site.
Figure 1. C/EBP activates the EDN promoter. A. HL60-eos cells were transfected by 
electroporation with the EDN promoter CAT construct (5 µg) in combination with 15 µg of 
either LNCX-CEBPγ, a C/EBP member that lacks the transactivation domain, the empty LNCX 
vector, a synthetic dominant negative (DN) C/EBP or the empty Rc-CMVneo expression vector. 
Transfection of either C/EBPγ or DN-C/EBP clearly reduces EDN promoter activity in HL60-eos 
cells. The activity of the EDN promoter CAT construct is roughly 10-fold higher that the activity 
of the promoterless CAT vector pBLCAT3 (data not shown). B. The EDN promoter (2µg) was 
co-transfected with different C/EBP family members (4µg) in COS-1 fi broblasts by the calcium 
phosphate precipitation method. Bars indicate the mean value of at least three independent 
experiments, standard deviation is indicated by error bars. CMV-LacZ co-transfection and β-
galactosidase assays were used to correct for variation in transfection effi ciency. The EDN 
promoter can be activated by C/EBPα, β, δ, and ε.
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To further study the importance of the C/EBP sites for the promoter /intronic enhancer activity, 
we prepared different point mutations in the background of the complete promoter/intron 
sequence. We mutated the fi rst C/EBP site (C/EBP ∆-144), the second (C/EBP ∆-124) or the 
third (C/EBP ∆+163) or all three of them (C/EBP 3∆). The activity of the different mutants was 
then tested in HL-60-eos cells (fi g.3B). Mutation of C/EBP –144 or C/EBP +163 had no effect on 
promoter/intron activity, while mutation of C/EBP -124 signifi cantly decreases the activity of the 
EDN promoter/intron. Activation of the EDN promoter is not further reduced after mutation of all 
three putative C/EBP binding sites in comparison with the single mutation of C/EBP –124.  These 
results indicate that activation of the EDN promoter/intron by C/EBP proteins is regulated by 
C/EBP -124. We also transfected the different mutants of the EDN promoter/intron in eosinophils 
Figure 2. Mapping of the C/EBP responsive sequences in the EDN promoter. A. Schematic 
representation of the EDN promoter and intron. Putative transcription factor binding sites are 
indicated as boxes. The arrows indicate the 5’ ends and the 3’ ends of the deletion constructs 
used in panel B. B. COS-1 cells were transfected with deletion constructs of the EDN promoter 
and the fi rst intron cloned into the promoterless pBLCAT3 (2µg) together with LNCX (control) 
or LNCX-C/EBPα (4µg). Two days after transfection cells were harvested and CAT activity was 
determined. Bars indicate the mean value of at least three independent experiments, standard 
deviation is indicated by error bars. CMV-LacZ co-transfection and β-galactosidase assays were 
used to correct for differences in transfection effi ciency. Deletion of the C/EBP -124  or C/EBP 
+163 sites results in a decrease in C/EBP-induced promoter activity.
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differentiated in vitro from cord blood CD34+ cells. As in HL-60-eos cells, there was no effect on 
promoter activity after mutation of -144 or +163. However, there was a signifi cant decrease in 
activity after mutation of the C/EBP -124 site (fi g. 3C). Mutation of all three C/EBP sites resulted 
in a reduction of promoter activity comparable to the single mutation of the C/EBP –124 site. 
These results indicate the importance of the C/EBP -124 site in eosinophils.
Figure 3. The C/EBP binding site at –124 is essential for EDN promoter activity in 
eosinophilic cells. A. Deletion constructs of the EDN promoter and the fi rst intron cloned into 
the promoterless pBLCAT3 (see legend 2A) (20µg) were transfected in HL-60 –eos cell s by 
electroporation.  Two days post-transfection, CAT activity was determined. Deletion of the C/
EBP -124 or C/EBP +163 sites results in a decrease in promoter activity. B. EDN-CAT constructs 
(20µg) containing the full promoter and intron with different point-mutations in the C/EBP sites 
were transfected in HL-60-eos cells. This fi gure shows that the C/EBP -124 binding site is crucial 
for promoter activity in HL60-eos cells. C. EDN-CAT constructs (20 µg) as described in B were 
transfected in eosinophils differentiated in vitro for 17 days as described under Materials and 
methods. The activity of the EDN promoter CAT construct is roughly 10-fold higher that the 
activity of the promoterless CAT vector pBLCAT3 (data not shown). As in HL60-eos cells, the 
C/EBP -124 binding site is also crucial for promoter activity in eosinophils.
Bars indicate the mean value of at least three independent experiments, standard deviation is 
indicated by error bars. CMV-LacZ co-transfection and β-galactosidase assays were used to 
correct for transfection effi ciency. 
C/EBP regulates the promoter of the EDN gene in human eosinophil cells
40
80
120
160
-
16
7
-
+
17
3
-
16
7
-
+
12
3
-
12
8
-
+
17
3
-
12
8
-
+
12
3
-
95
-
+
17
3
-
95
-
+
12
3
CA
T
Ac
tiv
ity
(%
)
200
20
40
60
80
100
120
140
ED
N
∆-
14
4
∆-
12
4
∆+
16
3
CA
T
Ac
tiv
ity
(%
)
HL60-eos
3∆
20
40
60
80
100
ED
N
∆-
14
4
∆-
12
4
∆+
16
3
CA
T
Ac
tiv
ity
(%
)
Eosinophils
120
3∆
A
B C
Chapter 2
46
Band shift analysis was used to investigate whether C/EBP proteins can interact with the C/
EBP -124 site. An oligonucleotide probe, containing the C/EBP -124 site, was end labeled and 
incubated with 10 µg nuclear extract of HL-60-eos cells. As shown in fi gure 4 the C/EBP -124 
site was able to bind several protein complexes (lane 1). Binding of the observed complexes was 
specifi c because binding could be competed with a 10-100 molar excess of cold self-oligo (lanes 
2 and 3). In contrast the binding could not be competed by the unrelated cAmp response element 
(CRE) site (lane 4). To further identify the proteins binding to C/EBP -124, extracts were pre-
incubated with specifi c antibodies against Ets2 or different C/EBP family members, includingα, 
-β, -ε. Antibody β ∆198 is able to bind all C/EBP family members. Figure 4 shows that all C/EBP 
antibodies induce a shift of the protein complex (lanes 6-9), whereas the unrelated Ets2 antibody 
is not able to induce a super shift (lane 5). These results indicate that C/EBPα, β, and ε proteins 
are able to bind to C/EBP –124 of the EDN promoter in HL-60-eos cells
Taken together, these results strongly suggest that multiple members of the C/EBP family are 
capable of interacting with the C/EBP site of the EDN promoter
Figure 4. Binding of different C/EBP proteins to the EDN promoter. Nuclear extracts were 
prepared from HL-60-eos cells. These extracts were then tested for C/EBP binding activity in a 
band shift assay using the –124 binding site as a probe. Lane 1 shows the binding of a complex 
binding to C/EBP -124, which can be competed with cold self-oligo (lanes 2 and 3), but not with 
the unrelated CRE site (lane 4). In lanes 1-4, only the shifted complex is shown. The DNA-protein 
complex can be supershifted (SS, open arrows) with antibodies against C/EBP α, β, and ε  and 
an antibody recognizing all C/EBP family members (lanes 6 to 10), but not with Ets antibodies 
(lane 5). The free DNA probe and the wells of the gel are indicated by closed arrows.
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Discussion
In this paper we show that C/EBP transcription factors are involved in the regulation of the EDN 
promoter. C/EBP proteins were previously implicated in the regulation of the myeloid colony 
stimulating factor receptors, like M-CSF37, G-CSF 38 and the common β chain of the IL-3/IL-5/
GM-CSF receptors 53, as well as in the regulation of some myeloid specifi c granule proteins, like 
MPO, neutrophilic elastase and lysozyme M 39,40. Importantly, this is the fi rst report describing a 
role for C/EBP proteins in human eosinophil-specifi c transcription, although the involvement of 
C/EBPs in chicken eosinophil-specifi c gene regulation was recently reported 41.
Members of the C/EBP family have been shown to have a changing temporal expression pattern 
during myeloid differentiation 42, 43. C/EBPα is expressed at high levels in early progenitors, C/
EBPβ and -δ become more prominent at later stages, while C/EBPε is only expressed during 
granulopoiesis 28,29. Alternative splicing and the ability of all members of the C/EBP family to 
form hetero- and homodimers as well as complexes with unrelated transcription factors lead to 
a variety of the possible DNA binding complexes 37,44-49. It is likely that these complexes have 
specifi c affi nities for particular binding sites and that this mechanism plays an important role in 
the specifi c regulation of certain genes by the C/EBP family. Selective expression of the different 
family members may also play a role in determining which C/EBP protein is important at a 
particular stage of differentiation. Different members of the C/EBP family can stimulate activity 
of the EDN promoter/intron in an overexpression system (Fig. 1B). However, our bandshift 
results show that in HL60-eos cells, which express endogenous EDN and C/EBP, C/EBPα, β, 
and ε interact with the EDN promoter. Since C/EBPα and ε have been shown to be important for 
granulocyte differentiation and are highly expressed in mature granulocytes, it is likely that these 
two are the most important regulators of EDN transcription in eosinophils. However, a more 
detailed analysis is required to determine the precise contribution of each C/EBP family member 
to EDN transcription in eosinophils.
We have shown that the C/EBP -124 site in the promoter of the EDN gene can bind C/EBP 
proteins (fi g 4). This is essential for optimal activity, since mutation of this site results in reduced 
promoter activity (fi g 3B). However, there is signifi cant residual promoter/intron activity after 
mutation of the –124 C/EBP site. This is likely due to activity of the PU.1 site, which we have 
previously shown to be involved in the regulation of the EDN gene 13. In the last few years it 
has become clear that the C/EBP family and PU.1, a hematopoietic-specifi c member of the Ets 
family, are key transcription factors in the regulation of myeloid-specifi c genes, including myeloid 
CSF receptors and myeloid granule proteins 37-40. Moreover, PU.1 and C/EBP proteins have also 
been shown to co-operate during eosinophilic differentiation in mice and chicken 17,37,50-52. In a 
previous study we have shown that the EDN gene is regulated by PU.1 13. In this study we report 
that C/EBP proteins also play a role in EDN expression, by binding to an upstream enhancer. 
This is the fi rst evidence of the role of C/EBP and PU.I in the regulation of an eosinophil-specifi c 
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gene. Interestingly, the C/EBP site is located in the upstream promoter and the PU.1 site in 
the fi rst intron, separated by 300 bp. Previous studies have shown the co-operation in gene 
regulation between PU.1 and C/EBP proteins whose binding sites were located close to each 
other 37, 38. However co-operation can also occur between C/EBP and PU.I sites separated by as 
much as 2kb, as we have recently shown for the promoter of the human IL-3R/IL-5R/GM-CSFR 
β chain 53.
In COS fi broblasts both the C/EBP -124 and the C/EBP +163 sites seem to be responsive to C/
EBPα co-transfection. However, in the hematopoietic cells, HL-60-eos and in vitro differentiated 
eosinophils, only the C/EBP -124 site is involved in EDN promoter activity. This difference might 
well be due to the overexpression of C/EBPα in the COS cells which might render the +163 site 
responsive, whereas the activation of the EDN promoter in HL-60-eos cells and eosinophils is 
regulated by moderate endogenous levels of C/EBP.
Taken together we have shown the involvement of C/EBP proteins in the regulation of the 
eosinophil-specifi c granule protein EDN. This is the fi rst example of eosinophil-specifi c gene 
regulation by C/EBP and PU.I. However, other eosinophil-specifi c genes are also expected to be 
regulated by these proteins, since both PU.1 and C/EBP (α and ε) are necessary for the in vivo 
differentiation of eosinophils.
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Abstract
Interleukin-5 (IL-5) plays a crucial role in the proliferation, differentiation and activation of 
eosinophils. The IL-5 receptor is composed of an IL-5-specifi c α subunit, which is expressed by 
eosinophils and basophils, and a βc-subunit shared with the receptors for IL-3 and GM-CSF. We 
identifi ed an AP-1 element which is important for IL-5Rα promoter activity. The AP-1 site and the 
previously identifi ed EOS1 site cooperate, since single mutation of either of the sites decreased 
promoter activity. We show that the AP-1 site of the IL-5Rα promoter binds multiple proteins, 
including cJun, CREB, and CREM.
Introduction
Cytokines such as interleukin-3 (IL-3) and GM-CSF are involved in the early differentiation of 
granulocytes, whereas the terminal differentiation of eosinophils selectively depends on IL-5 1; 2. 
Since a functional IL-5 receptor is only expressed on basophils and eosinophils, IL-5 controls the 
proliferation, differentiation, and functioning of eosinophils 3; 4. The IL-5 receptor (IL-5R) consist 
of two distinct membrane proteins, the α and β chain. The α-chain (IL-5Rα) is unique for the IL-
5R, is restricted to eosinophils and basophils and binds IL-5 with low affi nity 5-7. Expression of 
the IL-5Rα gene may be critical to the entry of multipotential myeloid progenitors into a particular 
hematopoietic developmental program. The β chain is shared with the receptors for IL-3 and GM-
CSF and is widely expressed in various hematopoietic lineages 8. The β-chain does not bind IL-5 
by itself, but is required for high affi nity binding 5; 9; 10.
The gene encoding the human IL-5Rα chain is located on chromosome 3. Recently the 5’ 
upstream region of this gene, containing multiple consensus sites for known hematopoietic 
transcription factors, was isolated, which appears to be highly active in the eosinophilic lineage 11. 
Sun et al. 12 identifi ed a unique enhancer-like cis element (EOS1) that is necessary and suffi cient 
for promoter activity and binds an unknown transcription factor. Besides this EOS1 site the 
promoter contains several consensus sites for known transcription factors. In this study we show 
the involvement of an AP-1 site in the regulation of the IL-5Rα gene. The AP-1 family is a set of 
sequence specifi c transcription factors, including the Jun, Fos, and activating transcription factor 
(ATF, including CREB and CREM) families, which form a variety of hetero- and homodimers 
13; 14
. Interestingly, AP-1 family members are known to be involved in the regulation of myeloid 
differentiation 15-17.
In this study we demonstrate that, besides the EOS1 site, the AP-1 element of the IL-5Rα 
promoter located between -440 and -432 is also involved in the regulation of the transcription. 
Therefore, the cooperative regulation of the unique EOS1 site and the AP-1 site is of great 
interest.
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Materials and Methods
Cell culture, reagents, and antibodies
Promyelocytic leukemia-HL-60 cells were cultured in RPMI 1640 (Life Technologies, Breda, 
The Netherlands.) supplemented with 8% fetal calf serum, (FCS, Hyclone) 100 U/ml penicillin 
(Life Technologies, Inc.), 100 µg/ml streptomycin (Life Technologies, Inc.) and 50µM β-
mercaptoethanol. HL-60 7.7 cells were generated by culturing HL-60 cells for two months at 
pH 7.7 in RPMI containing 25 mmol/L N-[2-Hydroxyethyl]piperazine-N’-3-propane-sulfonic acid 
(EPPS; Sigma, St Louis, MO). To further differentiate HL-60 7.7 cells butyric acid (0.5mmol/L; 
Sigma) was added up to 6 days. Polyclonal rabbit antibody against cJun was obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA). The antibodies against CREB and CREM were 
described previously 18.
Synthetic oligonucleotides and plasmid construction
The following oligonucleotides were used in this study (only the upper strands are shown): 
the AP-1 (5’-AGCTTAAATCATGTGTCAGTGTTGA-3’), AP-1 mutant (5’-AGCTTAAATCA
TGGGCCCGTGTTGA-3’), Col-TRE (5’-GATCTATCTGAGTCAGCAG-3’), c-jun TRE (5’- 
GATCTATCTGACATCAGCAG -3’), and SP1 (5’-AGCTTGGGGCGGGGCT-3’). A human 
genomic DNA library (λ Fix II, Stratagene) was screened using a random primed IL-5Rα probe 
(provided by Dr. B. Allet, Glaxo Institute). Secondary and tertiary screening was performed using 
an oligo corresponding to most of the fi rst exon (6). Isolated DNA fragments were cloned into 
the KpnI-NotI sites of the pBKS II phagemid (Stratagene). Fragments of the IL-5Rα upstream 
sequence were generated using the polymerase chain reaction with primers containing Hind III 
and Pst I sites for sense and antisense sequences, respectively, and ligated into the pCAT basic 
vector (Promega). Site-directed mutagenesis was performed as described by Kunkel 19.
Electro Mobility Shift Assay 
Nuclear extracts were prepared from the different HL-60 sublines following a previously described 
procedure 20. Oligonucleotides were labeled by fi lling in the cohesive with [α32P] dCTP using 
Klenow fragment of DNA polymerase I (Life Technologies, Inc.). Gel retardation assays were 
carried out according to published procedures with slight modifi cations 21. Briefl y, nuclear extracts 
were incubated in a total volume of 20 µl , containing 10mM HEPES-KOH pH 7.9, 50mM KCl, 
5mM MgCl2, 1mM EDTA, 10% (v/v) glycerol, 5mM DDT, 20 µg Bovine serum albumin (BSA), 2 
µg poly dI-dC (Pharmacia Biotech. Inc.) and 1 ng of a [α-32P]-labeled AP-1 oligonucleotide for 20 
minutes at room temperature. In competition experiments, indicated molar excess of unlabeled 
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oligonucleotide was added simultaneously with the [α-32P]-labeled oligonucleotide. Antibodies 
were incubated 30 minutes on ice prior to the addition of [α-32P]-labeled oligonucleotide. Protein-
DNA complexes were then separated on 5% non-denaturing polyacrylamide gels and visualized 
by autoradiography.
Transient transfection and CAT assay 
HL-60 cells were transfected by electroporation (280 V, 960 µF). Transfected cells were harvest 
for CAT assay after 48 hour. Cells were lysed by repeated freeze thawing in 250mM Tris pH 
7.4, 25mM EDTA Cellular extract was incubated in a total volume of 200 µl 200mM Tris pH 7.4, 
4% glycerol, 0.5mg/ml Butyryl CoA and 0.05µCi [14C]-Chloroamphenicol for two hours at 37°C. 
Reaction products where then extracted using 400 µl xylene/pristane (1:2), and the percentage 
of acetylated products was then determined using liquid scintillation counting. A CMV-lacZ 
construct was co-transfected to correct for differences in transfection effi ciency.
RNA isolation and Northern blotting
For Northern blotting, RNA (20µg) was electrophoretically separated on 0.8% agarose gel and 
transferred to Hybond (Amersham, Arlington Heights, IL). Blots were hybridized with randomly 
32P-labeled IL-5Rα, c-jun, or GAPDH fragments overnight at 42°C in hybridization buffer, 
washed, and exposed to fi lm as described previously 22.
Results
IL-5Rα expression was previously shown to be upregulated during eosinophilic differentiation of 
HL-60 clone 15 cells 10; 23. To investigate whether in HL-60 cells differentiated at pH 7.7 IL-5R 
expression is also responsive to BA, RNA was isolated from HL-60 7.7 cells treated for various 
periods with BA. Fig. 1 shows an increase in the expression of the IL-5R by BA treatment within 
4 days. Reprobing the blot with a GAPDH probe shows that equal amounts of RNA were loaded 
in each lane (fi g. 1). These results demonstrate that HL-60 7.7 cells are suitable for studying the 
regulation of the IL-5Rα promoter.
Previously it was shown that the EOS1 enhancer located at -430 to -422 was necessary for the 
activity of the IL-5Rα chain promoter in HL60 clone 15 cells 12. We transfected HL-60 7.7BA 
cells with a number of 5’ deletion constructs to determine the IL-5Rα chain promoter region 
essential for activity in eosinophilic cells. Figure 2A shows that deletion of a promoter region 
between -467 and -408 results in a complete loss of promoter activity in BA-differentiated HL60 
7.7 cells. This region contains the previously identifi ed EOS1 enhancer 12. However, sequence 
analysis of the promoter of the IL-5Rα chain revealed the presence of a potential AP-1 binding 
site (5’-ATGTGTCAG-3’), next to the previously identifi ed EOS1 site 12. Since members of the 
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AP-1 family are known as positive regulators of myeloid differentiation (15-17), it is interesting 
to determine whether the AP-1 site plays a role in promoter activity. Therefore the AP-1 site was 
mutated in the -467 construct and promoter activity was determined in HL-60 7.7BA cells. A 
single mutation of the AP-1 site resulted, like a mutation of the EOS1 site, in decreased activity 
of the construct (fi g. 2B). The activity of the construct having both the EOS1 and the AP-1 site 
mutated was comparable with background level (fi g. 2B). These results suggest that the EOS1 
and the AP-1 site are both involved in the regulation of the IL-5Rα gene.
To investigate the nature of the proteins binding to the putative AP-1 binding site in the IL-5Rα 
gene promoter, gel mobility shift assays with a radio-labeled double stranded oligonucleotide 
containing this AP-1 site were performed. Fig. 3A shows a complex that binds to this AP-1 
element in HL-60 7.7BA cells. The specifi city of the protein-complex binding to the AP-1 probe 
was demonstrated by competition with a 10-100-fold molar excess of either the unlabeled cold 
self-oligonucleotide (fi g. 3A). By contrast, oligonucleotides containing a mutated AP-1 site or an 
SP-1 binding site were not able to compete for binding (fi g 3A). To study the properties of the AP-
1 element, we examined the competition of this binding with known AP-1 sites. Oligos containing 
Figure 1. The expression of the IL-5Rα chain is upregulated during the differentiation 
of HL60 7.7 cells. RNA was isolated from HL60 7.7 cells treated for various times with butyric 
acid (BA, 0.5 mM) and analyzed for expression of the IL-5Rα chain gene, c-jun and GAPDH. 
Eosinophilic differentiation of HL60 7.7 cells is clearly accompanied by an increase in expression 
of the IL-5Rα chain and c-jun genes.
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a TPA (12-O-tetradecanoylphorbol-13-acetate) response element (TRE) from the collagenase 
promoter, or from the c-jun promoter were able to block the binding to the AP-1 site of the IL-5Rα 
promoter, although to somewhat different extends (fi g 3A). In addition, the binding could also 
blocked by an oligo containing a cAMP response element (CRE) (data not shown). These results 
indicate that these sites binds proteins or protein-complexes that are also able to bind the AP-1 
site of the IL-5Rα promoter. 
To further characterize the protein complex binding to the AP-1 binding site within the IL-
5Rα promoter, nuclear extracts of HL-60 7.7BA cells were incubated with antibodies against 
different AP-1 family members prior to detection of DNA-protein interactions by gel mobility 
shift assay. The antibodies against CREB, CREM and cJun induced a supershift of the labeled 
DNA probe (fi g. 3C), indicating that their respective antigens participate in the formation of the 
complex bound to the AP-1 site of the IL-5Rα promoter. In contrast, there was no supershift with 
antibodies against JunD, c-fos, and ATF3 (data not shown).
Figure 2. An AP-1 site in the promoter of IL-5Rα chain is involved in its activity in 
eosinophilic HL60 cells. A HL60 7.7 cells treated for three days with BA were transfected 
with various progressive 5’ deletion constructs of the IL-5R a chain promoter. Two days after 
transfection, CAT assays were performed to determine the regions of the IL-5Rα chain promoter 
involved in its eosinophilic activity. B IL-5Rα chain promoter constructs with mutations in either 
the EOS1 site or the AP-1 site were analyzed as described in A. It is clear that both the EOS1 
site and the AP-1 site are necessary for full promoter activity.
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While CREB and CREM are ubiquitously expressed proteins, the expression of cJun is tightly 
regulated. Therefore, we analyzed the expression of cJun mRNA in HL-60 7.7 cells after addition 
of BA which coincides with the increase in expression of the IL-5Rα gene (fi g. 1). There is a 
remarkable increase in the expression of cJun mRNA after four days of addition of BA. Treatment 
of HL-60 7.7 cells with retinoic acid, an inducer of neutrophilic HL-60 differentiation, does not 
effect cJun mRNA expression (data not shown). These results indicate that cJun expression is 
upregulated during eosinophilic differentiation of the HL-60 7.7 cell line, and is likely to play an 
important role in regulating IL-5Rα expression. 
Figure 3. The AP-1 site in the IL-5Rα chain promoter binds multiple AP-1 family proteins.
A Nuclear extracts isolated from HL60 7.7 cells treated for 4 days with BA were tested for proteins 
binding to the AP-1 site from the IL-5Rα chain promoter in a gel shift experiment. The specifi city 
of the complex was determined by competition with 10-100 fold molar excess of unlabeled self-
oligonucleotide of mutated AP-1 site, SP-1 site, collagenase TRE or c-jun TRE. B Mutation of the 
AP-1 site completely inhibits protein binding to the oligonucleotide, as shown by gel shift analysis 
using the wild-type or mutated AP-1 site from the IL-5Rα chain promoter as a probe. C Supershift 
analysis with antibodies to c-jun, CREB, CREM show the binding of these proteins to the AP-1 
site from the IL-5Rα chain promoter in HL60 7.7BA cells. An antibody to STAT3 was used as a 
negative control.
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Discussion
It has been previously reported that the activity of the IL-5Rα promoter is regulated by the EOS-1 
element which binds an unknown eosinophil specifi c factor 12. As shown in this study, expression 
of the IL-5Rα gene is also regulated by the AP-1 element of the promoter. Since single mutation 
of one of the sites dropped promoter activity, these results indicate that the proteins binding to 
the AP-1 site and EOS1 site cooperate which suggests that an eosinophil specifi c transcription 
factor cooperates with a general transcription factor and together regulate the expression of the 
IL-5Rα chain.
Gel retardation assays showed the binding of a nuclear protein complex to the AP-1 
oligonucleotide. This binding could be inhibited with the unlabeled self-oligonucleotide and also 
with other known AP-1 elements, such as a CRE site and TRE sites from the collagenase or 
the c-jun promoter. These results suggest that the AP-1 site of the IL-5Rα promoter is most 
related to the CRE which can bind dimers of the ATF family and TRE sites which binds cJun. 
We showed with supershift analysis the presence of the proteins cJun, CREB, and CREM in the 
shifted complex. There was not a supershift with antibodies against other AP-1 family members 
such as JunD, c-Fos, and ATF3. This suggests a role for cJun, CREB, and CREM in the binding 
complexes of the AP-1 site. The expression of cJun mRNA is increased during differentiation of 
HL-60 cells, indicating that cJun might play a role in eosinophil specifi c gene transcription. It may 
be that during eosinophilic differentiation the expression of the IL-5Rα chain gene is regulated 
by different protein complexes of AP-1 family members. Interestingly, others also found the 
involvement of AP-1 family members in the differentiation of myeloid cells 15-17.
Recently, a second promoter region for the IL-5Rα gene was identifi ed 24, located within the 
fi r st intron, between exon 1 and 2. This second promoter is only active in eosinophilic HL-60-
C15 cells and the nuclear factor binding to this promoter is also only present in these cells. The 
existence of another promoter site of the IL-5Rα chain suggests that the transcription of IL-5Rα 
is under the control of multiple promoters, like other genes such as insulin-like growth factor and 
colony stimulating factor 1 25; 26. It is possible that, during eosinophil maturation, an alternative 
use of the promoters may determine stage-specifi c expression of the IL-5Rα gene.
The production of eosinophils from bone marrow progenitors as well as the priming, activation, and 
enhanced survival of mature eosinophils is regulated by IL-5 1-4. Understanding the regulation of 
the IL-5Rα gene orders an opportunity in controlling the development, differentiation, activation, 
and prolonged survival of the mature eosinophils. We have shown the contribution of the AP-1 
site to this regulation. Further experiments need to be done to resolve the precise roles of the 
EOS1 and AP-1 elements and binding proteins.
An AP-1 site in the promoter of the IL-5Rα gene is necessary for promoter activity
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Abstract
The common β chain (βc) is the main signaling component of the heterodimeric receptors for 
IL-3, IL-5, and GM-CSF and is primarily expressed on myeloid cells. The proximal βc promoter 
is regulated by GGAA-binding proteins, including PU.1, a hematopoietic specifi c member of 
the Ets family. However, it is not likely that PU.1 alone accounts for the myeloid-restricted 
expression of the βc subunit. Here we describe the identifi cation of a C/EBP-binding enhancer 
that is located 2 kb upstream of the transcription start site. The enhancer contains two elements 
that bind C/EBPα and -β in U937 cells, while also C/EBPε is also bound in extracts of HL-60 cells. 
Importantly, deletion of the enhancer or mutation of either of one of the C/EBP sites results in a 
complete loss of promoter activity in cell lines as well as in primary cells, showing the importance 
of C/EBP members in βc gene activation. We further show that PU.1 has to cooperate with C/
EBP proteins to induce βc transcription. Since the βc is already expressed on CD34+ cells, these 
results demonstrate that both C/EBP and PU.1 are not only important for the myeloid-specifi c 
gene regulation at later stages of myeloid differentiation.
Introduction
Hematopoiesis is a developmental process in which pluripotent hematopoietic stem cells 
proliferate and differentiate to lineage-committed progenitors which eventually generate all 
kinds of mature, terminally differentiated blood cells 1. The multistep processes leading to the 
differentiation of CD34+ stem cells toward the erythroid, lymphoid, or myeloid lineages are, at 
least in part regulated by a network of cytokines. Of these, G-CSF, M-CSF, GM-CSF, IL-3, and 
IL-5 are implicated in the development of myeloid cells, which include monocytes/macrophages 
and the neutrophilic-, eosinophilic-, and basophilic granulocytes 2. Where IL-3 and GM-CSF act 
on early progenitors, IL-5, G-CSF, and M-CSF stimulate the late differentiation of eosinophilic, 
neutrophilic, and monocytic lineages, respectively 2-4. 
Although IL-5, IL-3, and GM-CSF all have distinct effects on different target cells, they elicit similar 
responses in cells responsive to all three cytokines and they even cross-compete for binding to 
the same cell 5,6. Molecular cloning of the receptor components and reconstitution of the functional 
receptors have revealed that the receptors for the three cytokines are heterodimers composed of 
a cytokine-specifi c α chain (IL-3Rα, IL-5Rα, and GM-CSFRα) and a common signaling β chain 
(βc) 7-9. Both the α and β chains are glycosylated proteins and members of the class I cytokine 
receptor family 10. Although the human βc subunit has no binding capacity by itself, it associates 
with the low affi nity α chains to form a high affi nity receptor 11-13. Besides its role in high affi nity 
binding, the βc chain plays a major role in IL-3, IL-5, and GM-CSF mediated signal transduction, 
explaining the functional overlap of these cytokines 14. Interestingly, the mouse has two β 
subunits, known as βc (AIC2B) and βIL-3 (AIC2A) 15,16. The mouse βc chain is the common β 
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subunit for the mouse IL-3, IL-5, and GM-CSF receptors, in analogy with the human βc. Although 
βc and βIL-3 have 91% homology at the amino acid level, βIL-3 binds IL-3 with low affi nity and 
does not form a high affi nity receptor with IL-5Rα and GM-CSFRα, in contradiction to βc 17. We 
previously reported the cloning of the human βc gene and the remainders of a βc pseudogene, 
suggesting a loss of βIL-3 in the human rather than murine-specifi c gene duplication 18.
In both the human and murine systems, binding of IL-3/IL-5/GM-CSF induces receptor 
multimerization, most likely in a ligand:α:β stoichiometry of 2:2:2 19. This leads to the activation 
of JAK2, a protein tyrosine kinase that is constitutively associated with the membrane-proximal 
region of the βc chain 20,21. Subsequently, signaling molecules of several signal transduction 
pathways are activated, including STAT5 22,23, p21Ras 24, ERK1/2 25, JNK/SAPK 26, p38 27, and 
PI3K 28,29(for a review, see 30). Because the βc subunit is involved in IL-3, IL-5, and GM-CSF 
signaling, expression of the βc chain is important for all myeloid cells and their precursors. 
Therefore, elucidating the factors that govern its expression will help to understand the events 
that regulate myeloid-lineage commitment.
 The βc chain is already expressed on hematopoietic CD34+ stem cells 31, while at later stages 
of differentiation expression of the βc chain is mainly restricted to the myeloid lineages 31. 
Uncovering the molecular mechanisms that drive its expression will contribute to understanding 
of the events of myeloid commitment and differentiation. In the last few years it has become 
clear that PU.1, a hematopoietic-specifi c member of the Ets family, and the C/EBP family are 
key transcription factors in myeloid-specifi c gene activation 32. Receptors that play a signifi cant 
role in myeloid development, such as the GM-CSFRα, G-CSFR, and the M-CSFR, have all been 
shown to be regulated by the combination of PU.1 and C/EBP proteins 33-35. Previous studies 
described the isolation of the genes for the human and murine βc/βIL-3 subunits 18, 36. We have 
shown that PU.1 and another, unidentifi ed GGAA-binding protein activate the human βc gene 
by binding to the proximal promoter region (at -65bp and -45bp relative to the transcription 
start site, respectively) 18. PU.1, a hematopoietic specifi c member of the Ets transcription factor 
family 37, is expressed in myeloid and B cells and has been shown to regulate a number of 
myeloid specifi c genes, including the M-CSFR 33, G-CSFR 34, GM-CSFRα 35, eosinophil-derived 
neurotoxin 38, myeloperoxidase 39, and PU.1 itself 40. Other factors that have been shown to be 
important for myeloid-specifi c promoter regulation are members of the CCAAT/enhancer binding 
protein (C/EBP) family. Members of the C/EBP family have been shown to have a changing 
temporal expression pattern during myeloid differentiation. C/EBPα is expressed at high levels 
in early progenitors, C/EBPβ and -δ become more prominent at later stages, while C/EBPε is only 
expressed during granulopoiesis 41-43. C/EBPα, a basic-region leucine zipper transcription factor, 
originally characterized in liver and adipose tissue 44, is expressed in early myeloid precursors 
41
 and has also been shown to be important for the expression of the M-CSFR, G-CSFR, and 
GM-CSFRα 33-35. Another C/EBP member that is important for myeloid gene expression is C/
EBPε, which was recently described to be strongly induced during granulocytic differentiation 
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42,43
. Gene targeting of both C/EBPα and C/EBPε results in impaired granulopoiesis 45,46, clearly 
demonstrating their roles in myeloid development.
Here we show that, analogous to the M-CSFR, G-CSFR, and GM-CSFRα, the βc is regulated 
by C/EBP members. We identifi ed a crucial enhancer located 2 kb upstream of the transcription 
start site that contains two C/EBP-binding motifs. Both sites are able to bind C/EBPα, -β, and -ε, 
while mutation of the sites results in a complete loss of promoter activity.
Materials and Methods
Cells, cDNAs, oligonucleotides, and antibodies
COS-1 cells were cultured in Dulbecco’s modifi es Eagle medium (DMEM; Life Technologies, 
Gaithersburg, MD) supplemented with 8% heat inactivated fetal calf serum (FCS; Life 
Technologies). The monocytic cell line U937 and the promyelocytic leukemia cell line HL-
60 were maintained in RPMI 1640 (Life Technologies) supplemented with 8% FetalClone I 
(HyClone, Logan, UT).
CD34+ cells were isolated from cord blood and differentiated as described by Caldenhoven et al. 
47
. In short, mononuclear cells were obtained by centrifugation of the blood on a Ficoll-Hypaque 
gradient (density 1.077 g/ml). Mononuclear cells were incubated with CD34+ antibody and 
magnetic beads, prior to positive selection on a column that was placed in a magnetic fi e ld. Cells 
were cultured in Iscove’s modifi ed Dulbecco medium (IMDM; Life Technologies) supplemented 
with 10% FCS, Stem Cell Factor (100 ng/ml), FLT-3 ligand (100 ng/ml), IL-3 (0.1nmol/l), GM-CSF 
(0.1nmol/l), and IL-5 (0.1nmol/l). After three days, cells were cultured in IMDM supplemented 
with 10% FCS, IL-3 and IL-5. From day 21, IL-3 was also omitted from the medium. Viability 
remained >95% throughout the 28-day experiment.
Human C/EBPα (a kind gift from Dr. G.W.M. Swart, University of Nijmegen, The Netherlands), 
hC/EBPβ (a kind gift from Prof. S. Akira, Hyogo College of Medicine, Nishinomoya, Japan), hC/
EBPγ (cloned by PCR from HL-60 cDNA), rat C/EBPδ (a kind gift from Prof. S.L. McKnight, John 
Hopkins University, Baltimore, MD), hC/EBPε (cloned by PCR from HL-60 cDNA), and PU.1 (a 
kind gift from Prof. R.M. Maki, Burnham Institute, La Jolla, CA) were cloned into the expression 
vector pLNCX (Clontech, Palo Alto, CA).
The following oligonucleotides were used in this study: for PCR cloning of C/EBPγ, γF (5’-
TGGCAAGGGAGAGTGCCCAA-3’) and γR (5’-TGAGGTCTACTG-TCCTGCAT-3’); for cloning of 
C/EBPε, εF (5’-TCAAGAGCAGTGGGGGCGGG-3’) and εR (5’-TCCACCAGCCAGCCTCAGCT-
3’); for site-directed mutagenesis of C/EBP site 1, ENHC1 mut (5’-AACTCAAAGGGGGG
GCCCACATGAAGGGTA-3’); for C/EBP-site 2, ENHC2 mut (5’-CTCTGTATTTTGCTCGA
GTTTCAGAATAAA-3’); andfor band-shift analysis (only upper strand is shown), C1 wt (5’-
AGCTTCAAAGGGGGTTTC-CACATGAAGGGA-3’), C1 mut (5’-AGCTTCAAAGGGGGGGC
CCACATGAAGGGA-3’), C2 wt (5’-AGCTTGCTCTGTATTTTGAAATAGTTTCAA-3’), C2 mut 
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(5’-AGCTTG-CTCTGTATTTTGCTCGAGTTTCAA-3’), and -65 (5’-AGCTTCCGGCACTGC-
TTCCTCTTTCTGCTA-3’).
The following antibodies were used in this study: anti-C/EBPα (rabbit polyclonal IgG 14AA, 
sc-061X; Santa Cruz Biotechnologies, Santa Cruz, CA), anti-C/EBPβ (rabbit polyclonal 
IgG C-19, sc-150X; Santa Cruz Biotechnologies), anti-C/EBPδ (rabbit polyclonal IgG M-17, 
sc-636X; Santa Cruz Biotechnologies), anti-C/EBPε (rabbit polyclonal IgG C-22, sc-158X; 
Santa Cruz Biotechnologies), and anti-Fli-1 (rabbit polyclonal IgG C-19, sc-356X; Santa Cruz 
Biotechnologies).
Plasmids for promoter analysis, transient transfection, and CAT assay
The 2.7-kb HindIII fragment of the βc subunit promoter (-2096/+600) was cloned into the HindIII 
site of the promoterless pBLCAT3 vector 48. Deletion construct -1967/+600CAT3 was generated 
by cloning the HincII- HindIII fragment (-1967/+600) into XbaI and XhoI sites of pBLCAT3 via the 
SmaI- HindIII sites of SK- (Stratagene). The 129 bp HindIII -HincII fragment (-2096 to -1967) was 
cloned into the HindIII and BamHI sites of pBLCAT2 48 and the HindIII and PstI sites of TATACAT 
49
 to generate HH129CAT2 and HH129TATA, respectively, via the HindIII and SmaI sites of a 
modifi ed pSG5 (Stratagene). The BglII site at -289 was used to generate -2096/-289CAT2 and 
-1967/-289CAT2. Site directed mutagenesis was performed according to the method of Kunkel 
50
.
For transfection experiments, COS-1 cells were cultured in six-well dishes (Nunc, Copenhagen, 
Denmark), and 3 h later, the cells were transfected with 6 µg of supercoiled plasmid DNA as 
described previously 51. Following 16 to 20 h exposure to the calcium-phosphate precipitate, 
medium was refreshed. Cells were harvested for CAT assays 24 h later. Transfection of 
U937, HL-60, eosinophils and neutrophils was performed by electroporation at 300V and 
960 µF (107 cells, 20 µg of supercoiled plasmid DNA). In co-transfection experiments 10 µg 
of promoter construct was transfected with 10 µg of cDNA. Two days after transfection cells 
were harvested for CAT assays. CAT assays were performed as follows. Cells were lysed by 
repeated freeze-thawing in 250 mM Tris (pH7.4) and 25 mM ethylenediaminetetraacetic acid 
(EDTA). Cellular extract was then incubated in a total volume of 200 µl containing 250 mM Tris 
(pH7.4), 2% glycerol, 0.3 mM Butyryl Coenzyme A (Sigma, St. Louis, MO), and 0.05 µCi of [14C] 
Chloroamphenicol (Amersham, Arlington Heights, IL) for 2 h at 37°C. Reaction products were 
then extracted using 400 µl of xylene/pristane (1:2), and the percentage of acetylated products 
was then determined using liquid scintillation counting. All experiments were performed at least 
four times. A LacZ reporter was used to correct for transfection effi ciency.
Gel retardation assay
Nuclear extracts were prepared from U937 and HL-60 cells following a previously described 
procedure 52. Oligonucleotide probes were labeled by fi lling in the cohesive ends with [α-32P]dCTP 
using Klenow fragment of DNA polymerase I. Gel retardation assays were performed as follows. 
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Nuclear extracts (10 µg) were incubated in a fi nal volume of 30 µL containing 10 mM Tris 
(pH7.4), 10% glycerol, 2 mM EDTA, 50 mM NaCl, 0.05% Nonidet P-40, 300 µg/ml bovine serum 
albumin (BSA), 30µg/ml poly(dI/dC), 0.5  mM dithiothreitol (DTT), and 1.0 ng of 32P-labeled probe 
for 20 min at room temperature. Complexes were then separated through non-denaturating 5% 
polyacrylamide gels and visualized by autoradiography. In competition experiments, a 10 to 100-
fold molar excess of wild type or mutated oligonucleotide was added to the reaction mix for 5 min 
before addition of the labeled probe. For supershift analysis, nuclear extracts were pre-incubated 
with 2µg antibody for 40 min on ice before the addition of the labeled probe.
Results
A 2-kb upstream enhancer regulates βc subunit expression
In a previous study we reported the isolation of a 2.7-kb HindIII fragment, which contains the 44 
bp exon 1, 2096 bp of upstream sequences, and 598 bp of the fi rst intron of the human βc subunit 
Figure 1. An upstream enhancer is crucial for βc promoter activity. A. U937 and HL-60 
cells were transfected with successive 5’ deletion constructs of the βc promoter cloned in the 
promoterless pBLCAT3 reporter. Two days after transfection CAT activity was determined. 
Construct -2096/+600CAT3, which is active in both cell types, contains the 44 bp exon 1, 2096 
bp of upstream sequences and 598 bp of the fi rst intron. Deletion of 129 bp at the 5’ end results 
in the complete loss of promoter activity. B. Constructs that lack the proximal promoter, with 
(-2096/-289), without (-1967/-289) the enhancer, and the isolated enhancer (-2096/-1967) were 
cloned into the pBLCAT2 vector, which contains the minimal thymidine kinase promoter. Deletion 
of the enhancer element again results in the loss of promoter activity, while the isolated enhancer 
element has maximal CAT activity. This fi gure demonstrates that the fragment from -2096 to 
-1967 bp contains a functionally important enhancer element. Bars indicate the mean value of at 
least three independent experiments; standard deviation is indicated by error bars.
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gene 18. After cloning into the promoterless pBLCAT3 reporter plasmid (-2096/+600CAT3), 
transfection experiments in monocytic U937 cells and promyelocytic leukemia HL-60 cells 
showed that this fragment contains a functionally active promoter. To localize cis-activating 
elements, successive 5’ deletion constructs were generated. The NdeI (at -566), EcoRI (at 
-1120), and SmaI (at -1334) sites were used to generate -566/+600CAT3, -1120/+600CAT3, 
and -1334/+600CAT3, respectively. As shown in fi gure 1A, these constructs completely lost 
their activity. Also construct -1967/+600CAT3, made by using the HincII site at -1967, has no 
promoter activity, suggesting that an important positively regulating element has to be present 
between -2096bp and -1967bp. To test this hypothesis, the 129bp HindIII -HincII fragment, as 
well as the fragments from -2096 to -289bp and from -1967 to -289bp were cloned into the 
pBLCAT2 vector, a reporter plasmid containing the minimal thymidine kinase promoter 48. The 
generated constructs -2096/-1967CAT2, -2096/-289CAT2, and -1967/-289CAT2 were then 
transfected into U937 cells and HL-60 cells and tested for promoter activity. Figure 1B shows 
that -2096/-289CAT2 is active in both cell types, while -1967/-289CAT2 has lost this capacity. 
Indeed, -2096/-1967CAT2 is highly active in both cell types, clearly demonstrating the presence 
of an enhancer between -2096bp and -1967bp.
The enhancer contains two C/EBP binding motifs
To localize potential transcription factor binding sites, the 129 bp enhancer sequence (fi g 2A) 
was subjected to the TFMATRIX transcription factor database (http://pdap1.trc.rwcp.or.jp/
research/db/TFSEARCH.html). As shown in fi gure 2A, one NFκB and two C/EBP binding sites 
were identifi ed. Because C/EBP family members play an important role in the constitutive and 
inducible expression of a number myeloid-specifi c genes, the putative C/EBP sites (C1 and C2, 
fi g  2A) were studied in further detail. Band shift analysis was used to investigate whether C1 and 
C2 were protein binding elements. Oligonucleotide probes, each spanning a single C/EBP site, 
were end labeled and incubated with 10 µg of U937 and HL-60 nuclear extract. Figure 2B shows 
that elements C1 and C2 are both able to bind a partially overlapping set of protein complexes 
(lanes 1 and 8). The binding of most complexes could be competed by addition of a 10 to 100-fold 
molar excess of cold self oligo (lanes 2-3 and 9-10), but not with mutant C1 (lanes 4-5), mutant C2 
(lanes 11-12), or non-related -65 oligo (lanes 6-7 and lanes 13-14), a sequence that specifi cally 
binds transcription factor PU.1 in HL-60 and U937 cells. One complex (indicated by an arrow) 
can also be competed with the mutated or non-related oligos. These results demonstrate the 
specifi city of the complexes binding to elements C1 and C2, except for the indicated complex. To 
further characterize the proteins binding to C1 and C2, the nuclear extracts were pre-incubated 
with specifi c antibodies against C/EBP members and Fli-1, a member of the Ets family. In HL-60 
cells, supershifted complexes appear when extracts are incubated with anti-C/EBPα, -β, and -ε 
(fi gure 2c, lanes 2, 3, and 5 for C1, lanes 8, 9, and 11 for C2), but not with anti-C/EBPδ (lanes 4 
and 10) and anti-Fli-1 control antibody (lanes 6 and 12). Pre-incubation with anti-C/EBPδ (lanes 4 
and 10) results in the disappearance of a complex (indicated by an arrow). It is not clear whether 
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this complex is C/EBPδ, because competition experiments (see above) suggested that this is a 
nonspecifi c complex. Almost identical results were obtained with U937 cells, but no supershift 
was observed when extracts were incubated with anti-C/EBPε (data not shown). Taken together, 
these results show that different C/EBP proteins, including C/EBPα, -β, and -ε can bind to two 
distinct elements in the upstream enhancer.
Figure 2. Two elements in the enhancer bind C/EBP-containing complexes. A. The 150 bp 
nucleotide sequence of the 5’ end of construct -2096/+600. The 129 bp HindIII/HinCII fragment 
was subjected to a transcription factor database; one NFκB site and two C/EBP binding 
elements (C1 and C2, underlined) were identifi ed. Nucleotides which were mutated to inhibit 
C/EBP binding are indicated in bold face. B. Nuclear extracts of HL-60 cells were incubated with 
oligonucleotides spanning a single C/EBP site and analyzed in a band shift assay. Elements C1 
and C2 bind a partially overlapping set of complexes (lanes 1 and 8), which can be competed 
with a 10 to 100 fold molar excess of cold self oligo (lanes 2, 3 and 9, 10). When mutant (C1mut 
and C2mut) or non-related oligo (-65, a PU.1 binding element) is used, only one complex is 
competed for binding (indicated by the arrow). C. Before addition of the labeled oligo, 2 µg of 
indicated antibody was added to nuclear extracts of HL-60 cells. Pre-incubation with antibodies 
against C/EBPα, -β, and -ε, but not with control antibody against Fli-1 results in the appearance 
of supershifted complexes (lower panel). The upper panel is a shorter exposure of the same 
gel. The arrow indicates the complex which disappears when anti-C/EBPδ is added. It is unclear 
whether this complex contains C/EBPδ, since fi gure 2A suggests that this is a non-specifi c 
complex. This fi gure shows that the enhancer contains two discrete elements that specifi cally 
bind C/EBPα, -β, and -ε in HL-60 nuclear extracts. In U937 cells similar results were obtained, 
only no binding of C/EBPε was detected.
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The C/EBP sites are essential for enhancer activity
To elucidate whether the C/EBP binding elements are functionally important, both C1 and 
C2 were mutated in the -2096/-1967CAT2 construct and tested for promoter activity in U937 
and HL-60 cells. Single mutation of either C1 or C2 already reduced promoter activity to the 
background level (fi g 3A), as occurs when both sites are mutated. These data show that both 
elements are essential for enhancer activity, and suggest the cooperation of the proteins binding 
to the elements. Next we co-transfected the wild type and mutant constructs with the cDNAs of 
several C/EBP family members. Probably due to a cryptic C/EBP site in the pBLCAT2 vector, 
co-transfection of C/EBP cDNAs with pBLCAT2 resulted in moderately enhanced background 
values (unpublished result). Therefore the enhancer constructs were cloned into the pLT-G 
plasmid, a CAT-vector with a synthetic TATA-box. Figure 3b shows that C/EBPα, -β, -δ, and 
-ε induced a 4-5 fold induction of CAT activity when co-transfected with the wild type -2096/-
1967 construct in HL-60 cells (similar results were obtained in U937 cells, not shown). When 
C/EBP elements C1 and C2 were mutated, the effect of C/EBP co-transfection was dramatically 
decreased. The transactivating capacity of C/EBPδ is of interest, because it is unclear whether 
this protein binds to the enhancer in a band shift assay (see above). Nevertheless, C/EBPδ binds 
to C1 and C2 when overexpressed in COS cells (data not shown).
To further demonstrate the importance of C/EBPs for enhancer activity, the -2096/-1967CAT2 
construct was also co-transfected with C/EBPγ, a dominant negative C/EBP member 53, and with 
an anti-sense construct of C/EBPα. As shown in fi gure 3c, co-transfection of anti-sense C/EBPα 
reduces promoter activity with 65% in U937 cells and with 50% in HL-60 cells, while C/EBPγ 
reduces promoter activity with 70% in both cell types. These results clearly demonstrate the role 
of C/EBP proteins in the regulation of the βc chain gene.
To demonstrate that the C/EBP sites also contribute to βc promoter activity in primary cells 
as opposed to tumor cell lines, we transfected the C1 and C2 double mutant in the -2096/-
1967CAT2 construct into in vitro differentiated eosinophils and neutrophils (see Materials and 
Methods). As we found for HL-60 and U937 cells (see Fig. 3A), mutation of the C/EBP sites 
signifi cantly reduces enhancer activity in both eosinophils and neutrophil (Fig. 3D). This clearly 
shows that these C/EBP sites are involved in βc promoter activity in primary cells.
C/EBP and PU.1 cooperate to activate the βc promoter in non-hematopoietic cells
We have previously shown that binding of PU.1 to a GGAA element at -65 bp relative to the 
transcription start site is crucial for βc chain expression. To more precisely elucidate the roles of 
PU.1 and C/EBP in βc chain expression, these factors were co-transfected with different promoter 
constructs in COS fi broblasts. Figure 4A shows that both PU.1 and C/EBPα enhanced the 
promoter activity of the full promoter construct -2096/+600CAT3 by about 10 fold. However, co-
transfection of C/EBPα together with PU.1 resulted in a 30 fold increase in promoter activity. As 
expected, C/EBPα could no longer activate transcription when the C/EBP enhancer was deleted 
(construct -1967/+600CAT3, fi gure 4A). Surprisingly, also PU.1 could no longer activate this 
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construct. This was not due to a PU.1 binding site in the -2096/-1967 sequence, because fi gure 
4B shows that co-transfection of PU.1 did not affect the activity of construct -2096/-1967CAT2, 
which is in contrast to co-transfection of C/EBPα. Construct -226/+33CAT3, which contains only 
the promoter proximal region, can only be induced by PU.1, not by C/EBPα (fi gure 4B, second 
panel). If trans-activation of the full promoter construct (-2096/+600CAT3) by PU.I is dependent 
on proteins binding to the C/EBP sites, this would suggest that COS cells contain endogenous 
binding activity for the C/EBP sites. Therefore, we performed band shift experiments with COS 
Figure 3. Enhancer activity is mediated via the C/EBP binding sites. A. C/EBP elements 
C1and C2 were mutated alone (m1 and m2, respectively) or both (m1-2) in the -2096/-1967CAT2 
construct and tested for activity in a CAT assay in both U937 and HL-60 cells. Single mutation 
of either of one of the sites reduces CAT activity to background level in both cell types. B. Co-
transfection in HL-60 cells of the wild type -2096/-1967 construct with cDNAs encoding C/EBPα 
, -β, -δ, and -ε results in 4-5 times increase of CAT activity, when compared to empty pLNCX 
(pL) vector. The double mutant is not responsive to C/EBP co-transfection. For this experiment 
the constructs were cloned into the pLT-G reporter, since C/EBP co-transfection has a moderate 
effect on empty pBLCAT2 vector. Similar results were obtained in U937 cells. C. Co-transfection 
of C/EBPγ, a C/EBP member that lacks the transactivation domain or anti-sense C/EBPα 
signifi cantly reduces promoter activity of -2096/-1967CAT2 in both U937 and HL-60 cells. This 
fi g ure shows that the C/EBP elements are responsive to C/EBPα to -ε and are both crucial in 
promoter activation. Bars indicate the mean value of at least three independent experiments; 
standard deviation is indicated by error bars.
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nuclear extracts. Indeed, binding site C2 binds a specifi c protein complex in COS cells, that can 
be competed with access unlabeled probe, but not with a mutated C2 sequence or an unrelated 
oligonucleotide (Fig. 4C). We did not observe specifi c binding activity for C1 in COS cells (data 
not shown). Taken together, these results indicate that PU.1 and C/EBP functionally cooperate 
to enhance βc expression, although their respective binding elements are not clustered as is 
described for the GM-CSFRα, G-CSFR, and M-CSFR promoters.
Figure 4. C/EBP and PU.1 cooperate in βc gene transcription. A. C/EBPα and PU.1 were 
co-transfected with different promoter constructs in COS fi broblasts by the calcium phosphate 
precipitation method. C/EBPα and PU.1 each induce a 10 fold transactivation when co-
transfected with the full promoter construct -2096/+600CAT3. When both factors are transfected 
a 30-fold induction is measured, indicating that these proteins cooperate in βc gene activation. 
The effect of both C/EBP and PU.1 overexpression is completely lost when the C/EBP-binding 
enhancer is deleted (-1967/+600CAT3). B. COS fi broblasts were transfected with different 
promoter constructs, C/EBPα and PU.1 by the calcium phosphate precipitation method. The 
upstream enhancer (-2096/-1967) does not contain a functional PU.1 site, while activity of the 
proximal promoter region (-226/+33) can be enhanced by PU.1, but not C/EBPα co-transfection. 
These results demonstrate that PU.1, binding to the promoter proximal region, can no longer 
activate the βc promoter in the absence of C/EBP in the context of the full promoter. Bars indicate 
the mean value of at least three independent experiments; standard deviation is indicated by 
error bars. C. Nuclear extracts of COS cells were incubated with an oligonucleotide spanning 
C/EBP site C2 and analyzed in a band shift assay. Element C2 binds a set of complexes, which 
can be competed with a 10 to 100 fold molar excess of cold self oligo. When mutant (C2mut) or 
non-related oligo (-65, a PU.1 binding element) is used, no competition was observed.
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Discussion
Members of the C/EBP family have been shown to have a changing temporal expression 
pattern during myeloid differentiation. C/EBPα is expressed at high levels in early progenitors, 
C/EBPβ and -δ become more prominent at later stages, while C/EBPε is only expressed during 
granulopoiesis 41-43. Alternative splicing and the ability of all members of the C/EBP family to form 
homo- and heterodimers leads to a variety of possible DNA-binding complexes. It is likely that 
these complexes have specifi c affi nities for particular binding sites and that this mechanism plays 
an important role in the specifi c regulation of certain genes by C/EBPs. In the βc subunit enhancer 
we identifi ed two different binding sites that bind multiple C/EBP containing complexes (fi gures 
2A and 2B). Both elements bind C/EBPα, -β, and -ε in HL-60, while in U937 cells, which  express 
C/EBPε at a very low level, only binding of C/EBPα and -β was observed. Binding of C/EBPδ is 
unclear. In a band shift assay, addition of anti-C/EBPδ antibody results in the disappearance of 
a specifi c DNA-binding complex. However, the same complex can be competed with mutant and 
non-related oligonucleotides, suggesting that this is a non-specifi c binding complex. On the other 
hand, C/EBPδ from transfected COS cells can bind both sites and C/EBPδ can transactivate the 
βc promoter in co-transfection experiments (data not shown; fi gure 3B). Experiments with murine 
embryonic stem cells and blastocysts have shown that transcription of βc and βIL-3 is induced at 
the same time as the CD34 gene 54. In CD34+ cells, the C/EBPα is the predominant expressed 
isoform 55 and, therefore, is likely to be involved in the initial induction of the βc subunit gene(s). 
Nevertheless, expression of βc/βIL-3 is unaffected in C/EBPα defi c ient mice, while expression of 
the G-CSFR is completely blocked 45. This might indicate that C/EBP members can compensate 
for each other in some, but not all, situations.
We have shown that both sites can bind C/EBP independently and that both sites are functional. 
Mutation of either site results in almost a complete loss of promoter activity in cell lines as well as 
in primary eosinophils and neutrophils (fi gure 3A and 3D), suggesting that both sites are crucial 
for transcription activation. However, it is not clear whether both sites are occupied by C/EBP 
simultaneously in vivo. Transcription could be reduced by co-transfection of C/EBPγ, a dominant 
negative C/EBP member, and anti sense C/EBPα, further demonstrating the specifi c binding of 
C/EBP proteins to the enhancer sequence (fi gure 3C). 
(Co)transfection experiments with different deletion constructs showed the cooperation of C/
EBP proteins and PU.1 in the regulation of the βc gene (fi gure 4), reinforcing the signifi cance 
of these transcription factors in myeloid development. The combination of C/EBPs and PU.1 is 
also important for G-CSFR, GM-CSFRα, and M-CSFR expression. Functional elements for both 
proteins have been identifi ed in the proximal promoters of these genes. The sites for PU.1 and C/
EBP are separated by 15 bp (GM-CSFRα), 35 bp (M-CSFR), or 85 bp (G-CSFR), indicating that 
both proteins are likely to interact. Furthermore, both elements are close to the transcription start 
site (<100 bp) 33-35. In the βc subunit promoter the situation is different. Two functional GGAA-
elements are present in the proximal promoter region, while important C/EBP binding sequences 
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are located 2 kb upstream. When isolated, the PU.1-binding proximal promoter sequence has a 
high activity (construct -226/+33, fi gure 4). Interestingly, in the full promoter context (construct 
-2096/+600), this activity is dependent on the C/EBP binding enhancer, because deletion of the 
enhancer (construct -1967/+600) results in the complete loss of promoter activity. This again 
suggests an interaction between C/EBPs and PU.1. Why binding of PU.1 is not enough to induce 
promoter activity of construct -1967/+600 is not known. Initial experiments opened the possibility 
that additional, yet unidentifi ed proteins play a role in βc gene activation. It is possible that this 
factor(s), PU.1 and C/EBP all have to be present to obtain a transcriptionally active complex, 
while in the absence of C/EBP the additional protein blocks transcription by PU.1. Although 
future experiments are necessary to identify possible additional promoter elements and/or 
proteins that are involved in βc subunit expression, we have shown that both PU.1 and C/EBP 
play a critical role in βc chain transcription.
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Abstract
We have investigated the role of C/EBP transcription factors during the IL-5 induced differentiation 
of human CD34+ cells towards eosinophils. For this purpose we used human umbilical cord blood 
derived CD34+ cells and cultured them in the presence IL-5. In this ex vivo system C/EBPα is 
expressed at high levels during the induction phase of differentiation and is down-regulated 
with maturation. C/EBPε on the other hand, is induced during differentiation of CD34+ cells and 
remains expressed at a high level until terminal differentiation. In order to establish whether C/
EBP proteins play a role in eosinophil differentiation, retroviral transductions were performed to 
ectopically express a dominant negative version of the C/EBP proteins. Transduction of CD34+ 
cells with DN-C/EBP results in an inhibition of proliferation and in a block of differentiation as 
shown by morphology. Proliferation decreased from a thirty times fold induction to a ten times 
fold induction. Using this ex vivo system of eosinophil differentiation we were able to induce 
seventy-fi ve percent juvenile eosinophils. On the other hand in cells transduced with DN-C/EBP 
remain in the blast stage and only four percent juvenile eosinophils could be detected. RNA 
of the common β chain of the IL-3/IL-5 and GM-CSF receptor was strongly decreased in cells 
ectopically expressing DN-C/EBP. These results show that C/EBP transcription factors are 
involved in both the proliferation and differentiation of human eosinophils. The control of the βc 
promoter provides a mechanism of how differentiation is regulated by C/EBP factors.
Introduction
Eosinophils are major effector cells in allergic diseases, such as allergic asthma 1; 2. They are 
recruited to and activated in lung tissue where they participate in processes that lead to tissue 
damage characteristic for the pathophysiology of allergic asthma 3-5. The pro-infl ammatory 
effects of eosinophils are mediated by the release of cytokines, chemokines and lipid mediators, 
such as TNF-α, IL-8, PAF, and LTC4 6; 7. Cytotoxic effects are provoked by reactive oxygen 
species produced by a membrane bound NADPH oxidase and by toxic basic proteins, such as 
major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and 
eosinophil-derived neurotoxin (EDN) 8-10. 
Eosinophils are derived from pluripotent hematopoietic stem cells (HSC) in the bone marrow11. 
These HSC’s are responsible for the maintenance of adequate numbers of terminally 
differentiated hematopoietic cells during health and disease 12. The HSC mature into fully 
differentiated eosinophils via the granulocyte/ erythrocyte/ macrophage/ megakaryocyte-colony 
forming unit (GEMM-CFU) and eosinophil/basophil-colony forming unit (EO/B-CFU) 13-16. Tight 
regulation of expression of cytokines, colony stimulating factors, their receptors, and transcription 
factors coordinate lineage specifi c differentiation. Interleukin-3 (IL-3), granulocyte macrophage 
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colony stimulating factor (GM-CSF), and IL-5 have been shown to play a major role in the 
differentiation of eosinophils 17-19. Development of hematopoietic cells is controlled by lineage-
specifi c transcription factors. CAATT/enhancer binding protein (C/EBP), PU.1, and c-myb have 
emerged as key regulators of gene expression during granulopoiesis 20-22.
The C/EBP family of transcription factors belongs to the basic region/leucine zipper (bZIP) 
transcription factors. The C/EBP proteins share structural and functional features and to date, 
six members have been cloned and characterized: C/EBPα, β, γ, δ, ε, and ζ 23-27. C/EBP proteins 
contain a carboxy-terminal dimerisation domain (leucine-zipper), a DNA-binding domain (basic-
region), and an N-terminal activation domain 27. C/EBPs can form homodimers and heterodimers 
with other C/EBP proteins and with other transcription factors via their leucine zipper region 27. 
In contrast to the other C/EBP members, which are widely expressed, C/EBPε is predominantly 
expressed at high levels in the late stages of granulopoiesis and in T-lymphocytes 28-30. The 
C/EBP family members are known to exert pleiotropic effects in the tissues in which they are 
expressed 30. This effect may be due to their tissue and differentiation-stage specifi c expression, 
their ability to dimerise with members of their own family of transcription factors, and their 
capability to interact with other transcription factors such as PU.1 and Fos/Jun.
C/EBPα has been shown to be expressed in early myeloid cells and to be involved in the 
regulation of a number of granulocyte-specifi c genes 20; 31-37. Mice defi cient in C/EBPα display 
an early block in the maturation of granulocytes 38. Both C/EBPβ and C/EBPδ play a role in 
mediating the infl ammatory responses 39. Recently C/EBPβ was described to play a role in the 
regulation of MBP 40. C/EBPε is essential for terminal differentiation and functional maturation of 
committed granulocyte progenitor cells. As a consequence of its characterization, using both in 
vitro and knockout mouse models, C/EBPε has been identifi ed as a critical regulator of terminal 
granulopoiesis and one of the causative mutations in a severe human disease, neutrophil-
specifi c granule defi ciency 41. 
In the present study, we have investigated the role of C/EBP transcription factors during the 
differentiation of human CD34+ cells towards eosinophils in the presence of IL-5. Our results 
demonstrate that C/EBPα is highly expressed at the beginning of eosinophil differentiation and is 
down-regulated during maturation. In contrast, C/EBPε is up-regulated during differentiation. In 
order to determine whether the C/EBP transcription factors play a role in eosinophil differentiation 
of human CD34+ cells, C/EBP proteins were inhibited during this process. For this purpose, we 
transduced CD34+ cells with a dominant negative C/EBP protein (DN-C/EBP), which prevents 
DNA binding of endogenous C/EBP proteinss. Our experiments demonstrate that C/EBPs play 
a role in the proliferation and maturation during eosinophil differentiation. Ectopic expression of 
DN-C/EBP results in an inhibition of proliferation. Inhibition of C/EBP proteins results in a block 
of differentiation. These data clearly demonstrate that C/EBP transcription factors play a critical 
role in the differentiation of human eosinophils.
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Materials & Methods
Cell isolation and Culturing 
Isolation and culturing of human CD34 positive cells. CD34 positive cells were isolated as 
previously described 42. In short, mononuclear cells were isolated from umbilical cord blood by 
density centrifugation over a fi coll-paque solution (density 1.077 g/ml). CD34 positive cells were 
isolated by MACS immuno-magnetic cell separation (Miltenyi Biotech, Auburn, USA) using 
a hapten conjugated antibody against CD34, which was coupled to magnetic beads. CD34 
positive cells were cultured in Iscove’s Modifi ed Dulbecco’s Medium (IMDM; Gibco, Paisly, 
UK) supplemented with 10% heat inactivated fetal calf serum (FCS; Life Technologies, Breda, 
The Netherlands), 50 mM b-Mercaptoethanol, 100 U/ml penicillin (Life Technologies), 100 
µg/ml streptomycin (Life Technologies) and 2mM Glutamine (Gibco, Paisly, UK) at a density of 
250.000 cells/ml. Cells were differentiated towards eosinophils upon addition of SCF (50 ng/ml 
Pepro Tech, London, UK), FLT-3 ligand (50 ng/ml Pepro Tech, London, UK), GM-CSF (0,1 
nmol/l Endogen, Hmapshire, UK), IL-3 (0,1 nmol/l Strathmann, Hamburg, Germany), and IL-5 
(0,1 nmol/l a kind gift from Dr. M. McKinnon, GSK, UK). Every 3 or 4 days, cells were counted 
and diluted in fresh medium to a density of 500.000 cells/ml and the cytokines IL-3 and IL-5 were 
added to the cells.
Culturing of Phoenix-A. The Phoenix-Ampho cells, a 293T-based amphotropic retroviral 
packaging cell line  43, were cultured in Dulbecco’s modifi ed Eagle medium (DMEM; Life 
Technologies) supplemented with 8% heat inactivated FCS (Life Technologies), 100 U/ml 
penicillin (Life Technologies), and 100 µg/ml streptomycin (Life Technologies).
Constructs
We used a bicistronic retroviral DNA construct with a gene of interest and a marker gene encoding 
for eGFP (LZRS-IRES-eGFP) or murine CD8α (LZRS-IRES-Lyt-2) down-stream of an Internal 
Ribosomal Entry Site (IRES), allowing independent translation of the products of both genes in 
the transduced target cells. DN-C/EBP coding sequence was cloned from the pLNCX DN-C/EBP 
plasmid 44 in the Nae I site from the LZRS-IRES-eGFP to obtain the retroviral vector LZRS-DN-
C/EBP-IRES-eGFP and from LZRS-DN-C/EBP-IRES-eGFP between the BstB I and Not I sites 
into the LZRS- IRES-Lyt-2 to obtain the retroviral vector LZRS-DN-C/EBP-IRES-Lyt-2.
The EDN promoter/intron (-300 to +298, GENBANK X16546) was cloned by PCR using human 
genomic DNA 45. The amplifi ed fragment was then sequenced and cloned into the promoterless 
luciferase reporter plasmid pGL3 (Promega). 
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Retroviral Transduction of CD34+ cells
Helper-free recombinant retrovirus was produced by stable transfection of the amphotropic 
retroviral packaging cell line, Phoenix-ampho, by calcium phosphate co-precipitation. Cells 
were plated in 6 cm dishes 24 hours before transfection. 5 Minutes prior to transfection 25 
mM Chloroquine diphosphate was added to the cells. A total of 10 µg of DNA was used per 
transfection. Medium was refreshed, 16 hours after transfection. After an additional 24 hours, 
cells were split into 75 cm2 dishes (Greiner, Alphen a/d Rijn, The Netherlands) and 2 mM 
Puromycin was added to the cells. After two weeks of selection, cells were plated into 25 cm2 
dishes (Greiner) and were grown to a confl uence of 90%. Subsequently cells were grown in a 
minimal amount of medium for 24 hours. Viral supernatants were collected and fi ltered through 
a 0.45 µm fi lter.
CD34 positive cells were transduced after two days of differentiation in 24 wells dishes coated 
with 20 µg/ cm2 recombinant human fi bronectin fragment CH-296 (RetroNectin; Takara, Otsu, 
Japan), and 2% Bovine Serum Albumin (BSA). Transduction was performed by addition of 0.5 
ml viral supernatant to 0.5 ml medium containing 500.000 cells. 24 Hours after transduction 0.7 
ml medium was removed from the cells and 0.5 fresh virus supernatant was added to the cells 
together with 0.5 ml fresh medium and cytokines. The percentage of eGFP positive, living cells 
was determined every 3 or 4 days by FACS-analysis (FACSvantage, Becton Dickinson, San 
Jose, CA) containing 1 µg of propidium iodide (PI)/ml. 
Immuno-histochemistry staining of cytospins
The percentage of eosinophil differentiation was determined by histochemical staining of the 
cells. Cytospins were prepared from 5 x 104 differentiated eosinophils. Slides were dried on 
silica gel for 24 hours before fi xing them in dry-acetone for 10 minutes. The percentage of cells 
differentiating towards eosinophils was determined by Luxol Fast Blue staining (Avocado Res. 
Chem. Ltd., Heysham, UK), a dye specifi cally staining granules of eosinophils. Slides were 
stained with 0.15 % w/v Luxol Fast Blue in urea saturated ethanol for 2 hours.
Giemsa May-Grünwald staining was also used to analyze differentiating eosinophils. Cytospins 
were stained in a 50% Eosin Methylene Blue solution according to May-Grünwald (Sigma-
Aldrich GmbH, Seelze, Germany) for 20 minutes, rinsed in water for  5 seconds, and the nuclei 
were counter-stained with 10% Giemsa solution (Merck kGaA, Darmstadt, Germany) for 15 
minutes. During eosinophil differentiation, different stages of maturation can be observed. Cells 
differentiate from blast cells towards pro-myelocyte type I, pro-myelocyte type II, myelocyte, 
meta-myelocyte, and fi nally mature eosinophils with segmented nuclei. These stages can be 
distinguished by the size of the cells, ratio of cytoplasm versus nucleus present, presence of 
azurophilic granules, appearance of eosinophilic granules and the shape of the nuclei. ‘Juvenile’ 
eosinophils were, in our experiments characterized as cells belonging to the stages of pro-
myelocyte II, myelocyte, metamyelocyte and mature eosinophils. These cells were all observed 
to contain eosinophilic granules.
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Transient transfection and Luciferase assay 
Transfection of in vitro differentiated eosinophils was performed by electroporation at 300 V 
and 950 µF (5.106 cells, 10 µg supercoiled plasmid DNA) 44. 24 hours after transfection, cells 
were harvested and lysed in commercially available luciferase lysis buffer. CMV-Renilla co-
transfection was used to correct for variations in transfection effi ciency. Luciferase activity was 
measured with the Lumat LB 9507 luminometer (EG&G Berthold, Bad Wildbad, Germany).
Western Blotting
For the detection of C/EBPα, C/EBPε, and DN-C/EBP differentiating eosinophils were lysed in 
Laemmli sample buffer (0.12 M Tris/HCl [pH 6.8], 4% SDS, 20% glycerol, 0.05% bromophenol 
blue, and 35µM β-mercaptoethanol). Total cell lysates were boiled for 5 min at 95°C and equal 
amount of protein were analyzed by SDS-polyacrylamide gel electrophoresis. Proteins were 
transferred to Immobilon-P and incubated with blocking buffer (10mM Tris/HCl [pH 8.0], 150 
mM NaCl and 0.3% Tween-20) supplemented with 5% dried non-fat milk. Blots were incubated 
overnight at 4°C with appropriate antibodies (1:1000) and after hybridization with secondary 
antibodies developed utilizing Enhanced Chemiluminescence (ECL, Amersham. UK). 
The following antibodies were used: anti-C/EBPα (rabbit polyclonal IgG 14aa, sc-061X; Santa 
Cruz, San Jose,CA), anti-C/EBPε (rabbit polyclonal IgG C-22, sc-158X; Santa Cruz). 
Apoptosis
For the analysis of apoptosis by Annexin-V staining cells were washed with ice-cold PBS, 
resuspended in binding buffer (10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, and 2.5 mM 
CaCl2). Cells were then incubated with phycoerythrin (PE)-conjugated Annexin-V for 30 min on 
ice and fl uorescence was analyzed by FACS-analysis (FACSvantage, Becton Dickinson, San 
Jose, CA), by measuring a total cell count of 10,000 cells per sample.
For detection of Lyt-2, cells were stained with fl uorescein isothiocyanate (FITC)-conjugated Lyt-2 
antibody (BD Pharmingen). After staining, cells were washed twice in phosphate-buffered saline 
(PBS) and analyzed by fl ow cytometry. All steps of the staining procedure were performed on 
ice, and appropriate fl uorochrome-conjugated, isotype-matched control antibodies were used in 
all experiments.
Reverse transcriptase-PCR (RT-PCR) assays. 
RNA was isolated from FACS-sorted differentiating eosinophils as described previously 46, 
reverse transcribed using a poly-dT15 oligonucleotide (Invitrogen, Breda, The Netherlands) and 
400 U of Maloney murine leukemia virus (M-MuLV) reverse transcriptase (Invitrogen) at 37°C 
for 1 hour. Semi-quantitative PCR assays were performed in 30 mL reaction volumes using the 
appropriate diluted amounts of cDNA template, 2 mmol/L MgCl2, 0.25 mmol/L each dNTP, 10 
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pmol/L of each primer, and 0.8 U Taq polymerase (Roche, Basel, Switzerland) in 1x buffer (10 
mmol/L Tris-HCl, pH 8.5, 50 mmol/L KCl). Reaction conditions were a 10 minute denaturing 
step at 94°C followed by 30 cycles of 1 minute at 95°C, 1.5 minute at 56°C, and 2 minute at 
72°C. PCR products were separated on 1% agarose gels, stained with ethidium bromide. Three 
separate FL donor pools were analyzed and each PCR was repeated 4 to 6 times. The βc, IL-
5Rα and β-actin primers that were used are as follows: βcR: CTGTGGCTATACCCATGAGC; 
βcR: TCAAACCCTGACTTCACAGG; IL-5RαF: CACACTGGGGAGAAATATCG; IL-5RαR: 
CGAGTTCCTTCAATCTCTGC. For β-actinF and β-actinR primers see 47.
Results
Expression pattern of C/EBPα and C/EBPε during eosinophil differentiation of CD34+ 
cells.
Members of the C/EBP transcription factor family play a role in the differentiation and lineage 
commitment of eosinophils. In mice and human cell lines C/EBPα is expressed in early myeloid 
progenitors, and its expression decreases as these progenitors differentiate into mature 
granulocytes 48. In turn, C/EBPε is up-regulated at the promyelocyte or myelocyte stage, as 
shown in mice and human cell lines 28; 49. To investigate the role of C/EBP transcription factors in 
human eosinophil development derived from CD34+ cells, we fi rst examined the expression levels 
of C/EBPα and C/EBPε. Therefore, CD34+ progenitor cells isolated from umbilical cord blood 
were differentiated towards eosinophils in the presence of the cytokines IL-3 and IL-5. Protein 
lysates were made at different time-points during differentiation. Proteins were separated on 
12% SDS-PAGE by electrophoresis and western blotting was performed with antibodies against 
C/EBPα and C/EBPε. As shown in fi gure 1A C/EBPα is expressed up to day 7 and expression 
decreases during differentiation, but remains present. C/EBPε levels are increasing from day 
3 to 14 and remains expressed at a high level (Fig. 1B). These experiments show that in this 
human ex vivo system C/EBPα is expressed at high levels upon induction of differentiation and 
is down-regulated with maturation. On the other hand, C/EBPε is induced during differentiation 
of CD34+ cells in vitro and remains at a high level. This is in agreement with the data obtained 
from aforementioned cell lines
Retroviral transduction of CD34+ cells with DN-C/EBP. 
In order to investigate the role of C/EBP proteins during differentiation of CD34+ cells towards 
eosinophils we used a C/EBP construct which act as a dominant negative variant, because 
the basic region has been replaced with a designed acidic amphipathic helix 50. This alteration 
prevents the basic region from binding to DNA and therefore inhibits DNA binding of endogenous 
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C/EBPs. To show the effect of this construct on transcription activation, isolated CD34+ cells were 
differentiated towards eosinophils and after 14 days transfected with the construct containing 
DN-C/EBP and a reporter construct. The luciferase reporter construct is down-stream of the EDN 
promoter, which is under the control of C/EBP transcription factors 44. Two days after transfection 
luciferase activity was measured. Figure 2A shows an inhibition of EDN promoter activity of 
approximately 80%, the amount of inhibition is comparable to the eosinophilic HL-60-eos cell 
line, which we have shown before 44. We cloned the dominant negative C/EBP into a retroviral 
vector, this construct contains beside the DN-C/EBP construct also a marker, eGFP (Fig. 2B; 
upper scheme) or the extracellular part of murine CD8 (Fig. 2B; lower scheme). The marker 
is downstream of an Internal Ribosomal Entry Site (IRES), allowing independent translation 
of the products of both genes. We differentiate isolated CD34+ cells towards eosinophils with 
IL-3 and IL-5 and transduced them at day two with the viral construct containing DN-C/EBP. 
After three days the percentage of eGFP positive cells was determined by FACS analysis, 
transduction effi ciencies were 45.9% ± 1.5% (n = 8; a representative experiment is shown in Fig 
2C). Expression of DN-C/EBP in transduced cells was confi rmed by western blotting of protein 
lysates from transduced cells with a C/EBPα antibody, which is cross-reactive with DN-C/EBP 
(fi g. 2D). Taken together, we showed that a DN-C/EBP construct inhibits the transactivation of 
EDN, which is under the control of C/EBP proteins, in CD34+ cells differentiated with IL-3 and 
IL-5. CD34+ cells express DN-C/EBP after viral transduction. 
Figure 1 Altered expression of C/EBPα and ε in differentiating eosinophils. CD34+ cells 
isolated from cord blood were differentiated towards eosinophils. Protein lysates were made at 
day 7, 10, 14, and 17. Western Blot analysis was performed with an antibody against C/EBPα 
(Fig 1A, top panel) and an antibody against C/EBPε (Fig. 1B, bottom panel). The experiment 
shown is representative of three additional experiments. 
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Inhibition of C/EBP proteins in differentiating eosinophils results in inhibited proliferation, 
but not cell death. 
To determine the role of C/EBP transcription factors in regulating eosinophil differentiation, 
isolated CD34+ cells were transduced with virus obtained from cells transfected with either 
LZRS-IRES-eGFP or LZRS-DN-C/EBP-IRES-eGFP. Proliferation was determined by counting 
the total amount of eGFP positive cells. Transduction of cells with the empty vector resulted in a 
proliferation of approximately 30 fold between day 7 and day 21. In contrast, transduction of cells 
with DN-C/EBP resulted in a diminished proliferation between day 7 and day 21 of approximately 
Figure 2 Retroviral transduction of CD34+ cells with DN-C/EBP. A CD34+ cells were 
differentiated towards eosinophils and transfected at day 14 with DN-C/EBP or the empty 
vector. Two days after transfection luciferase activity was measured. Results are expressed 
as percentage ± S.E.M. of four individual experiments. B A schematic representation of the 
LZRS DN-C/EBP constructs. The DN-C/EBP has been designed by replacing the basic region 
of C/EBP α with an acidic amphipatic helix. Therefore it can bind to all B-ZIP transcription 
factors and prevents DNA binding. As marker genes eGFP (top panel) or Lyt-2 (bottom panel) 
was used, which were under the control of an Internal Ribosomal Entry Site (IRES). C CD34+ 
cells were transduced with retrovirus and three days after transfection measured on the FACS, 
a representative fi gure is shown. D CD34+ cells were transduced with virus from QNX-A cells 
transfected with the LZRS-IRES-eGFP vector (1) or with the LZRS-DN-C/EBP-IRES-eGFP 
(2.105 (2) or 1.106 (3) infectious virus particles/ml). Three days after transduction cells were 
lysed and samples were analysed by SDS-PAGE. The experiment shown is representative of 
three additional experiments. 
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10 fold (fi gure 3A). These data demonstrates that C/EBPs are involved in the regulation of 
proliferation during eosinophil differentiation. 
To investigate if the decrease in proliferation of cells transduced with DN-C/EBP was due to a 
stop in proliferation or enhanced cell death we measured the amount of annexin-V positive cells 
during the differentiation of transduced cells as a read-out of early apoptosis. Surprisingly, we 
could not detect apoptosis in cells expressing eGFP. As shown in fi g 2C hardly any cell was 
double positive for eGFP and PI. Also detection of annexin-PE and eGFP appeared not to be 
possible. Together these data indicate that soluble eGFP leaks from dying cells. This was also 
mentioned by Harvey et al. 51.Therefore, we transduced cells with the virus obtained from cells 
transfected with LZRS-IRES-Lyt-2 or LZRS-DN-C/EBP-IRES-Lyt-2, because Lyt-2 is membrane-
bound and therefore can not leak out of the cell.
As shown in fi gure 3B there was no signifi cant difference in the amount of annexin-V positive 
cells between the LZRS-IRES-Lyt-2 transduced cells and the cells transduced with LZRS-DN-C/
EBP-IRES-Lyt-2. These results indicate that the decrease in the proliferation of cells transduced 
with DN-C/EBP was not mediated by accelerated apoptosis. 
Figure 3 Ectopic expression of DN-C/EBP results in inhibition of proliferation. A CD34+ 
cells were transduced with LZRS-IRES-eGFP or LZRS-DN-C/EBP-IRES-eGFP. Proliferation 
was determined by counting the eGFP positive cells. Results are expressed as fold increase 
in cell numbers compared with day 7 as an average ± S.E.M. of fi ve individual experiments. B 
CD34+ cells were transduced with LZRS-IRES-Lyt-2 or LZRS-DN-C/EBP-IRES-Lyt-2. At day 10, 
14, 17, and 21 cells were stained with an FITC-labeled antibody against Lyt-2 and a PE-labeled 
antibody against Annexin-V. Results are expressed as an average ± S.E.M. of three individual 
experiments. 
*
 Indicates a signifi cant difference compared with the EGFP control P < 0.05.
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Transduction of DN-C/EBP avoids eosinophilic differentiation of CD34+ cells.
In order to investigate if C/EBP proteins play a role in eosinophil differentiation, CD34+ cells were 
differentiated with IL-3 and IL-5 towards eosinophils and transduced with either LZRS-IRES-
eGFP or LZRS-DN-C/EBP-IRES-eGFP virus. After 10, 14, 17, and 21 days of differentiation, 
eGFP positive cells were sorted by the FACS from the non-transduced cells and cytospins were 
prepared. The morphology of the differentiating eosinophils was analyzed by histological May-
Grünwald Giemsa staining. Differentiation of cells transduced with eGFP resulted in about twenty 
percent juvenile eosinophils at day 10 and increases up to nearly 75% after 21 days (fi g. 4A). On 
the other hand transduction of cells with DN-C/EBP resulted, after 21 days of differentiation, in 
a low percentage of juvenile eosinophils of approximately four percent. The cells remain in the 
blast stage.
To further characterize the role of endogenous C/EBP in eosinophil differentiation, cytospins of 
transduced cells were also analyzed by Luxol Fast Blue (LFB) staining, an eosinophil granule-
specifi c dye. After 10 days of differentiation, about 33% of the cells transduced with eGFP were 
positive for LFB. This percentage increased to almost 70% after 21 days of differentiation. In 
contrast, differentiation of cells transduced with DN-C/EBP results in approximately 10% LFB 
positive cells after 21 days (fi g. 4B). These data indicate that C/EBP proteins play an important 
role in eosinophil differentiation.
Figure 4 Ectopic expression of DN-C/EBP results in inhibition of differentiation. CD34+ 
cells were transduced with LZRS-IRES-eGFP or LZRS-DN-C/EBP-IRES-eGFP. After 10, 14, 17, 
and 21 days of differentiation transduced cells were separated from the non-transduced cells, 
and cytospins were made. A Cytospins were stained with the Giemsa May-Grünwald solution. 
The percentage of progenitors and juvenile eosinophils was expressed as an average ± S.E.M. 
of fi ve individual experiments. B Cytospins were stained with the Luxol Fast Blue for 2 hours after 
fi x ation with dry-acetone and determined by microscopy. The percentage of LFB positive cells 
was expressed as an average ± S.E.M. of four individual experiments. 
*
 Indicates a signifi cant 
difference compared with the EGFP control P < 0.05.
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Reduced expression of IL-5R on CD34+ cells differentiated towards eosinophils in the 
presence of DN-C/EBP.
C/EBPα knockout mice have greatly reduced granulocyte colony stimulating factor receptor 
(G-CSFR) expression and responsiveness 38. Stimulation of CD34+ cells with G-CSF results in 
neutrophils 21. The IL-5R consist of a common β chain which is shared with the receptors for IL-3 
and GM-CSF and a specifi c α chain 52; 53. Since we have shown before that C/EBP is involved in 
the regulation of transcription of the common beta chain, we want to examine the role of C/EBP 
proteins on expression of the IL-5 receptor (IL-5R) 54. For this purpose, we transduced CD34+ 
cells cultured with IL-3 and IL-5 with either eGFP or DN-C/EBP and after 10 days eGFP positive 
cells were sorted by the FACS from the non-transduced cells. RNA was isolated from these cells 
and a semi-quantitative RT-PCR was performed. As shown in fi gure 5 cells transduced with DN-
C/EBP show a marked decrease in IL-5β mRNA expression. We also found a reduction of the 
amount of IL-5Rα mRNA. These results indicate that DN-C/EBP inhibits the expression of mRNA 
of both the IL-5Rα and the IL-5Rβ chain in transduced cells.
Figure 5 Inhibition of C/EBP 
proteins results in down-
regulation of βc mRNA. CD34+ 
cells were transduced with 
LZRS-IRES-eGFP or LZRS-DN-
C/EBP-IRES-eGFP. After 10, 14, 
17, and 21 days of differentiation 
transduced cells were separated 
from the non-transduced cells, 
RNA was isolated and semi-
quantitative PCR assays were 
performed using gene-specifi c 
primers. Each of the RT-PCR 
reactions was performed with two 
different batches of RNA.
Discussion
In this report we have investigated the role of the C/EBP transcription factors during eosinophil 
differentiation. We showed the expression patterns of C/EBPα and C/EBPε during eosinophil 
differentiation. We have shown that the expression of C/EBPα is high during the early stages 
of eosinophil differentiation By contrast, C/EBPε seems more involved in the latter maturation 
of eosinophils because of its augmented expression during differentiation. These patterns were 
illustrated before; however these experiments were done in mice and in cell lines 28; 48; 49. 
In order to examine the effect of inhibition of C/EBP, we used an ex-vivo differentiation system 
of umbilical cord blood cells. CD34+ cells were isolated and differentiated towards eosinophil in
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the presence of IL-3 and IL-5, which results in a high percentage of juvenile eosinophils 55. The 
multiplicity of the C/EBP family made it necessary to make use of a dominant inhibitory protein 
for this purpose, which prevents DNA binding of endogenous C/EBPs. The presence of several 
C/EBPs in the myeloid lineages suggests that related family members might compensate in vivo 
for the lack of a single isoform, just as GATA family members partially compensate for the lack 
of GATA-1 56. Potential redundancy is evident from the ability of C/EBPβ to compensate for the 
loss of C/EBPα in hepatocytes and from the ability of both C/EBPα and C/EBPε to direct the 
granulocytic differentiation of myeloblastic cell lines 57-60. The ability of DN-C/EBP to interfere with 
the multiple C/EBPs avoids compensatory effects that can arise in gene knockouts. 
Retroviral transduction experiments were performed in human CD34+ cells to express a 
dominant negative C/EBP. Specifi city of DN-C/EBP was demonstrated in differentiating 
eosinophils by inhibition of transcription activity of the EDN gene (see fi g 2A). We examined 
the effect of C/EBP proteins on eosinophil differentiation. The differentiation judged by the 
morphology of the cells was strongly inhibited in cell transduced with the retrovirus containing 
DN-C/EBP. This is consistent with the fi ndings in knock-out mice and the involvement of C/EBP 
proteins in the regulation of lineage-specifi c proteins 38. C/EBPα knockout mice lack neutrophils 
and eosinophils but retain monocytes, lymhocytes, erythroid cells and immature myeloblasts 38. 
They do not develop granulocytic colony forming units in vitro 38; 61. C/EBP ε knockout mice are 
normal at birth and fertile, however, they fail to produce eosinophils. Neutrophils are present in 
defi cient mice, but have an atypical nuclear morphology compared with wild-type neutrophils 62. 
C/EBP transcription factors are also involved in the activation of genes specifi c in the eosinophilic 
lineage, like EDN, MBP and eos47(avian) 40; 44; 63. Taken together, C/EBP proteins are important 
regulators of eosinophilic differentiation, as inhibition results in a block at the stage of early 
progenitors.
Transduction of differentiating eosinophils with DN-C/EBP, results in an inhibition of both 
proliferation and differentiation. This is a remarkable result, because generally induction of 
differentiation is accompanied by a decrease of proliferation. The inhibition of proliferation and 
differentiation might be due to the design of the DN-C/EBP which is based on C/EBPα. It is 
known that C/EBPα is an inhibitor of cell proliferation when over-expressed in cultured cells 30; 
64
. In addition, hepatocytes from newborn C/EBPα-defi cient mice display increased proliferative 
activity 65. Although C/EBPα is a transcription factor, its ability to arrest growth does not require 
its DNA binding activity, but is mediated via protein-protein interaction 66. C/EBPα has been 
found to interact with several proteins that are involved in the control of cell cycle progression, 
thereby indicating the existence of multiple pathways through which C/EBPα mediates growth 
arrest 66-71. C/EBPα may inhibit the proliferation via interaction with E2F or with cdk2 68; 72-74. 
However, interaction with cdk2 occurs via the C/EBPα basic region, and this segment is altered 
in DN-C/EBP 74. Taken together this might indicate that the DN-C/EBP, which dominant negative 
is for transcriptional activity of C/EBP family members, acts as an activator for protein-protein 
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interactions. However, we can not rule out that the C/EBP proteins are involved in the proliferation 
by gene regulation.
Inhibition of C/EBP activity during eosinophil differentiation results in strong inhibition of the 
expression of endogenous IL-5Rβ RNA. This is consistent with the fi nding that C/EBPα directly 
activates the IL-5Rβ promoter 54. IL-5-/-, IL-5Rα-/-, and β
c
-/-
 mice retain lower, but detectable levels 
of eosinophil 75-77. In addition, in neutrophils C/EBPα is involved in activation of the promoter of 
the granulocyte colony stimulating factor receptor (G-CSFR) 34; 35. G-CSF is a lineage-specifi c 
cytokine involved in the differentiation of neutrophils. C/EBPα knockout mice lack G-CSF 
responsive progenitors and have no mature neutrophils and no mature eosinophils 38. This might 
indicate that C/EBP proteins play a role in the differentiation of both neutrophils and eosinophils 
by regulation of the receptor involved in specifi c differentiation signals. IL-5 has been shown to 
regulate the expression of the IL-5 receptor α-subunit 78. We also observed a decrease in the 
expression of IL-5Rα mRNA. This might be due to the reduced transcription of the βc gene and 
impaired IL-5 signaling.
In summary, differentiation of human primary eosinophils is controlled by C/EBP transcription 
factors. Proliferation of human CD34+ cells was severely inhibited by the expression of a DN-
C/EBP. Cells expressing DN-C/EBP remain in the blast stage, did not undergo apoptosis. 
Furthermore, we conclude that C/EBPs contribute to eosinophilopoiesis via induction of the 
common β gene. Future experiments will focus on identifying the role that each C/EBP isoform 
plays in these regulatory processes. 
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Abstract
Granulocyte colony-stimulating factor (G-CSF) is the major regulator of granulopoiesis and acts 
through binding to its specifi c receptor (G-CSF-R) on neutrophilic progenitors. G-CSF induces 
granulocytic differentiation in the murine myeloid cell line 32D. Hematopoietic differentiation is 
regulated by lineage-specifi c transcription factors, such as C/EBPε. We have investigated the 
role of the C/EBPε transcription factor in the G-CSF induced granulocytic differentiation of the 
murine 32D cell line. To investigate the role of C/EBPε in the early differentiation of granulocytes, 
we used a 4-hydroxy-tamoxifen inducible system allowing the activation of C/EBPε within 
minutes. Cells expressing C/EBPε cultured in the presence of G-CSF showed an accelerated 
differentiation after 24h, both on granulocyte-specifi c marker expression and morphology. 
Using the system of 4-hydroxy-tamoxifen induced C/EBPε activation we showed that C/EBPε is 
rate-limiting in G-CSF induced granulocytic differentiation. Furthermore, we show a decreased 
proliferation of 32D cells expressing C/EBPε cultured in the presence of G-CSF. These results 
demonstrate that C/EBPε and G-CSF cooperate in the induction of granulocytic differentiation. 
Expression of C/EBPε turns out to be rate-limiting in the differentiation of granulocytes.
Introduction
The maintenance of adequate numbers of terminally differentiated hematopoietic cells during 
health and or disease is ultimately regulated by the continuous self-renewal, controlled 
proliferation, and differentiation of hematopoietic stem cells 1; 2. Closely regulated expression 
of cytokines, colony-stimulating factors, receptors, and transcription factors coordinate lineage 
differentiation from pluripotent stem cells into erythroid, myeloid, and lymphoid precursors 3; 4.
In the myeloid lineage CCAAT/enhancer-binding proteins (C/EBP) play a role in the differentiation. 
The C/EBPfamily consists of six members, including the highly related C/EBPα, C/EBPβ, C/
EBPδ, and C/EBPε, and the less related C/EBPγ and C/EBPζ 5-12. They belong to the basic 
region/leucine zipper (bZIP) family of transcription factors. C/EBP proteins contain a basic amino 
acid domain and a leucine zipper region allowing the formation of homo- and heterodimers 13. 
They share similar DNA binding specifi cities (13). The C/EBPs serve as critical regulators in the 
differentiation processes of a variety of mammalian cells including adipocytes, hepatocytes, and 
myeloid cells 14; 15. In contrast to the other C/EBP members, which are widely expressed, C/EBPε 
is only expressed at high levels in the late stages of granulopoiesis and in T-lymphocytes 16. 
The C/EBP family members are known to exert pleiotropic effects in the tissues in which they 
are expressed 17. This effect may be due to their tissue- and differentiation-stage specifi c 
expression, their ability to dimerise with members of their own family of transcription factors, and 
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their capability to interact with other transcription factors 13; 17. C/EBPε is essential for terminal 
differentiation and functional maturation of committed granulocyte progenitor cells (18). C/EBPε 
has been identifi ed as a critical regulator of terminal granulopoiesis and one of the causative 
mutations in the human disease, neutrophil-specifi c granule defi ciency 19-21. 
Granulocyte-Colony Stimulating Factor (G-CSF) stimulates both the proliferation and 
differentiation of granulocyte precursor cells 22-24. It also stimulates a variety of responses in 
mature neutrophils, including prolonged survival, phagocytosis, and superoxide production 25-
27
. G-CSF binds to its receptor (G-CSFR) on the cell surface to form a homodimeric receptor 
complex 28. The membrane-proximal region of G-CSFR has been shown to be essential for the 
transmission of growth signals via JAK2 activation, STAT3 and STAT5 phosphorylation, and 
MAP kinase phosphorylation 29-32. Accumulated evidence indicates that G-CSF and its receptor 
are essential for hematopoietic development and that G-CSF may be implicated in malignant 
disease 29; 33. 
The precise role that cytokines play in the early commitment to a particular cell lineage remains 
to be fully defi ned. It is still an open issue whether cytokines are involved in the lineage decisions 
of multipotent cells by directing a particular cellular pathway or on the other hand merely support 
the survival of cells that have intrinsically selected a specifi c hematopoietic lineage 34; 35.
In the present study we have investigated the role of C/EBPε in the differentiation of 32D cells. 
We especially focused on the effects of C/EBPε on the induction of differentiation. Therefore we 
used a tamoxifen-inducible system, which is characterized by a silenced transcriptional activity of 
C/EBPε until tamoxifen is added. We show that both G-CSF signaling and C/EBPε are important 
to induce granulocytic differentiation in 32D cells and C/EBPε is rate limiting in this process. 
Materials & Methods
Cell Culturing
32D.C8.6, a subline of the IL-3-dependent murine myeloid cell line 32D, stably expressing the 
human G-CSF-R, was generated as described previously 36. Cells were maintained in RPMI 
1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS;Gibco), 100 
U/ml penicillin (Life Technologies), 100 µg/ml streptomycin (Life Technologies), 2mM Glutamine 
(Gibco) and recombinant mouse IL-3 produced in COS cells 37. 
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Facs analysis and proliferation assay
To induce differentiation, the cells were washed twice with phosphate-buffered saline and cells 
were incubated at an initial density of 1×105 cells/mL in 10% FBS/RPMI medium supplemented 
with murine IL-3, 100ng/mL of human G-CSF (a kind gift of Dr R. Fijnheer, UMC) or 100ng/mL of 
human G-CSF and 500 nM 4-Hydroxy-tamoxifen (4OHT; Sigma) The medium was replenished 
every 2 to 4 days, and the cell densities were adjusted to 1 to 2 × 105 cells/mL. Viable cells were 
counted every 24 h by trypan blue exclusion. 
For the analysis of GR-1 expression a terminal differentiation marker, differentiating 32D C/
EBPε-ER cells were washed with ice-cold PBS, stained with R-phycoerythrin (PE)-conjugated 
Ly-6G (Gr-1; BD Pharmingen) After staining, cells were washed twice in phosphate-buffered 
saline (PBS) and antibody fl uorescence was analyzed by FACS-analysis (FACSvantage, 
Becton Dickinson), by measuring a total cell count of 10,000 cells per sample.
Constructs and Generation of stable cell lines 
pSG5 C/EBPε-ER was generated by cloning C/EBPε without the stop codon into SK+-ER 67. The 
C/EBPε-ER was cloned by PCR into the pSG513 vector and verifi ed by sequencing. To obtain 
32D cells stably expressing C/EBPε-ER 5 × 106 32D cells were electroporated (280 V, 950 
µF) with 10 µg expression vector and selected in 500 µg/mL G418 (Boehringer GmbH) in the 
presence of murine IL-3. The clones were obtained by limiting dilution and expression of C/EBPε-
ER was examined using Western blot analysis (see below).
Immuno-histochemistry staining of cytospins
The percentage neutrophil differentiation was determined by histochemical staining of the cells. 
Cytospins were prepared from 5 x 104 differentiated 32D cells. Slides were dried on silica gel for 
24 hours before fi xing them in dry-acetone for 10 minutes. Giemsa May-Grünwald staining was 
used to analyze 32D cells differentiating towards neutrophils. Cytospins were stained in a 50% 
Eosin Methylene Blue solution according to May-Grünwald (Sigma-Aldrich GmbH) for 20 minutes, 
rinsed in water for  5 seconds, and the nuclei were counter-stained with 10% Giemsa solution 
(Merck kGaA) for 15 minutes. During neutrophil differentiation, different stages of maturation 
can be observed. Cells differentiate from blast cells towards cells with a banded nucleus, a 
segmented nucleus and fi nally neutrophils with highly-segmented nuclei. These stages can be 
distinguished by the size of the cells, ratio of cytoplasm versus nucleus, neutrophilic granule-
containing cytoplasm, and the shape of the nuclei.
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Western Blotting
For the detection of C/EBPε-ER 32D cells were lysed in Laemmli sample buffer (0.12 M Tris/HCl 
[pH 6.8], 4% SDS, 20% glycerol, 0.05% bromophenol blue, and 35µM β-mercaptoethanol). Total 
cell lysates were boiled for 5 min at 95°C and equal amount of protein were analyzed by SDS-
polyacrylamide gel electrophoresis. Proteins were transferred to Immobilon-P and incubated 
with blocking buffer (10mM Tris/HCl [pH 8.0], 150 mM NaCl and 0.3% Tween-20) supplemented 
with 5% dried non-fat milk. Blots were incubated overnight at 4°C with anti-ERα (MC-20, Santa 
Cruz) or anti C/EBPε (sc-158X, Santa Cruz) and after hybridization with secondary antibodies 
developed utilizing Enhanced Chemiluminescence (ECL, Amersham). Blots were subsequently 
probed with β-actin antibody (Santa-Cruz, sc-1616) to confi rm equal protein loading.
Results and Discussion
C/EBPε is a downstream target of G-CSF signalling
G-CSF and C/EBPε play an important role in myeloid development. Mice defi cient in either G-
CSF or its receptor have a reduced amount of neutrophils (38-40). C/EBPε knockout mice have 
impaired granulopoiesis and myelodysplasia 41. They produce morphologically and functionally 
abnormal granulocytes. In addition, functional loss of C/EBPε is causativein the development 
of neutrophil specifi c granule defi ciency (SGD). SGD is a rare congenital disorder in which the 
neutrophils display atypical bilobed nuclei, lack expression of granule proteins; and possess 
defects in chemotaxis, disaggregation, receptor upregulation, and bactericidal activity. G-CSF 
induces granulocytic differentiation in the murine myeloid cell line 32D. Both G-CSF and C/EBPε 
Figure 1. Upregulation of C/EBPε expression during granulocytic differentiation of 32D 
cells 32D cells were washed twice in PBS and cultured in the presence of G-CSF or IL-3. Cells 
were lysed at the indicated time-points and samples were analysed by SDS-PAGE. Western 
Blot analysis was performed with an antibody against C/EBPε. The experiment shown is 
representative of two additional experiments. 
IL-3 1 2 3 5 7
days G-CSF
C/EBP ε
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are regulators of myeloid differentiation in 32D cells. In medium containing IL-3, 32D cells grow 
and maintain blast-like morphologic characteristics. However when exposed to G-CSF the 32D 
cell line differentiated to neutrophils 33. We used a 32D clone which  lacks the murine G-CSF 
receptor, but it ectopically express the human G-CSF receptor. We fi rst addressed the question 
whether G-CSF induces C/EBPε in 32D cells. Therefore, we cultured 32D cells in the presence 
of G-CSF to induce granulocytic differentiation. When cultured with IL-3 there is no expression 
of C/EBPε (fi gure 1). G-CSF clearly induced C/EBPε expression in 32D cells after one day of 
stimulation. Expression reached the maximum level in 5 days. These results indicate that C/
EBPε is upregulated during G-CSF induced granulocytic-differentiation.
Expression of Inducible C/EBPε Construct in 32D Cells
To better defi ne the role of C/EBPε in differentiation processes in granulocytes, we used an 
inducible system. This system uses the expression of a fusion between C/EBPε and a mutated 
ligand-binding domain from the estrogen receptor (ER). This protein is silenced by binding of 
heat-shock proteins and therefore not functional. In the absence of the inducer, 4-hydroxy-
tamoxifen (4-OHT), the C/EBPε–ER fusion is bound to heat-shock proteins. Addition of 4-OHT 
results in release of the heat-shock proteins from the C/EBPε–ER fusion protein. Using this 
inducible-system gave us the opportunity to examine the direct effects of the expression of C/
EBPε on granulocyte development. Generation of stable cell lines takes weeks. Therefore, the 
fi r st effect of the protein can not be examined. In contrast, addition of 4-OHT to the inducible 
system results in the rapid release of C/EBPε and effects are detectable within minutes. 
To investigate the role of C/EBPε in granulocytic differentiation, we stably expressed C/EBPε-
ER or the ER segment alone in 32D cells. By limiting dilution we obtained 17 clones, which 
were assessed for expression of the introduced proteins by western blotting (Figure 2). We did 
not observe any difference in the proliferation of the 32D C/EBPε-ER compared to the parental 
32D or 32D ER cells in IL-3 (data not shown, fi g 5). We have generated 32D clones expressing 
C/EBPε-ER, in which the activity of C/EBPε is silenced giving the possibility of investigation the 
direct actions of C/EBPε. 
Effect of Inducible C/EBPε Expression on G-CSF-Induced Granulocyte Differentiation of 
32D Cells
We next examined the correlation between C/EBPε expression and granulocytic differentiation. 
The expression of Gr-1, a GPI-anchored protein, is directly correlated with granulocyte 
differentiation and maturation 42. Expression of the granulocytic marker GR-1 in response to G-
CSF and 4-OHT was evaluated in these cell lines by FACS-analysis. There was no expression 
of GR-1 in both the 32D ER and the 32D C/EBPε-ER cells cultured in IL-3 (fi gure 3). After 3 
days the expression of Gr-1 increases in 32D ER and in 32D C/EBPε-ER cells cultured in the 
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presence of G-CSF (fi gure 3B and 3E). However in 32D C/EBPε-ER cells cultured in G-CSF in 
the presence of 4-OHT expression of Gr-1 was already enhanced after 24h (fi gure 3D). This 
enhanced expression of the differentiation marker Gr-1 was observed in all 17 different clones. In 
contrast in 32D ER cells cultured in the presence of G-CSF and 4-OHT there was no difference 
in the expression of Gr-1 compared to G-CSF alone (fi gure 3A). We show that induction of 
both G-CSF receptor signalling and C/EBPε resulted in an improved differentiation compared 
to differentiation induced with only G-CSF. This indicates that the induction of C/EBPε by G-
CSF is an important step in the regulation of granulocyte differentiation. In response to different 
concentrations of 4-OHT 32D C/EBPε-ER cells showed dose-dependent differentiation in the 
presence of G-CSF (data not shown). 
In contrast to our data, Nakajima and Ihle reported that expression of C/EBPε alone was suffi cient 
to induce granulocytic differentiation in 32D cells 43. In some clones we also observed an induced 
expression of the granulocytic marker Gr-1 after 7 days of culturing cells in the presence of 
4-OHT. However, this induction was only observed in cells with a high expression level of C/
EBPε-ER and not in cells with a lower expression level (fi gure 3C and 3F). This indicates that 
granulocyte differentiation induced by high levels of C/EBPε might be due to overexpression. In 
conclusion, we show that C/EBPε is rate-limiting in granulocytic differentiation of 32D cells.
Figure 2. Generating stable cells expressing C/EBPε-ER. A 32D cells were transfected with 
C/EBPε-ER by electroporation. Clones were obtained by limiting dilution in the presence of G418. 
Selected clones were lysed and samples were analysed by SDS-PAGE. Western Blot analysis 
was performed with an antibody against the ER unit. The experiment shown is representative of 
two additional experiments. B Blot were subsequently probed with β-actin antibody to confi rm 
equal protein loading.
β-actin
ER 39 41 44 45 48
clone
C/EBP ε-ER
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Effect of Inducible C/EBPε Expression on Morphology of G-CSF-Induced 32D Cells 
To further characterize the role of C/EBPε in the differentiation of neutrophils, we also examined 
the morphology of the cells during differentiation. Therefore we cultured 32D C/EBPε-ER and 
32D-ER cells in G-CSF in the presence or absence of 4-OHT. We prepared cytospins at different 
time-points. The morphology of the differentiating 32D cells was analyzed by histological May-
Grünwald Giemsa staining. Induction of differentiation of cells in the presence of G-CSF resulted 
in 21 percent banded neutrophils at day 1 and 20 percent segmented neutrophils after 3 days 
(fi g. 4). Induction of differentiation of 32D C/EBPε-ER cells with G-CSF and 4-OHT resulted 
in 56 percent banded neutrophils at day 1 and 30 percent segmented neutrophils after 3 
days. We show that beside the up-regulated expression of the granulocytic Gr-1 marker also 
morphologically the 32D C/EBPε-ER cells show an enhanced differentiation in the presence of 
G-CSF and 4-OHT. 
Figure 3. C/EBPε enhances G-CSF induced expression of granulocyte marker Gr-1. 32D-
ER and 32D C/EBPε-ER cells were cultured in the presence of IL-3 or G-CSF in the presence or 
absence of 4-OHT. After 24h and 72 h cells were washed, stained with a PE-labelled antibody 
against Gr-1. All procedures were performed at 4° C. Cells were measured on the FACS and a 
representative experiment is shown.
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Effect of Inducible C/EBPε Expression on Proliferation of G-CSF-Induced 32D Cells 
Induction of differentiation is associated with growth arrest and thus reduced proliferation. 
Therefore we examined whether the enhanced differentiation of 32D C/EBPε-ER in the 
presence of G-CSF and 4-OHT also resulted in a more pronounced reduction of the proliferation. 
To study the proliferation, 32D C/EBPε-ER and 32D-ER cells were seeded in IL-3 or G-CSF in 
the presence or absence of 4-OHT and viable cell counts were made daily (Figure 5). The 4-
OHT did not alter the growth of 32D-ER and 32D- C/EBPε-ER cells in the presence of IL-3. In 
the presence of G-CSF there is a decrease in the proliferation as shown before 44. We did not 
observe a difference in proliferation of 32D-ER cells cultured in G-CSF and 4-OHT. However, 
32D- C/EBPε-ER cells exposed to G-CSF and 4-OHT showed a small but signifi cant decrease of 
proliferation compared to cells grown in G-CSF alone.
Figure 4. C/EBPε enhances granulocytic morphology during G-CSF induced granulocytic 
differentiation. Cytospins were made, stained with the May-Grünwald Giemsa solution and 
determined by microscopy. The percentage of blast, banded, segmented or highly-segmented 
granulocytes is shown as an average of two individual experiments.
32D ER
32D C/EBPε-ER
0
20
40
60
80
100
0 1 3
days cultured
0
20
40
60
80
100
0 1 3
days cultured
days cultured
0
20
40
60
80
100
0 1 3
blast
banded
segmented
0
20
40
60
80
100
0 1 3
days cultured
blast
banded
segmented
G-CSF G-CSF + 4-OHT
A
DC
B
Chapter 6
112 113
It is tempting to speculate about the reduced proliferation upon induction of C/EBPε. C-myc 
is one of the critical regulators of cellular proliferation 45-47. C-myc is expressed in proliferating 
cells, whereas C/EBPs are expressed in differentiated cells 47; 48. Over-expression of c-myc 
blocks differentiation in many cell types 49-51. In 32D cells, over-expression of c-myc also blocks 
differentiation by G-CSF, but the underlying molecular mechanism of this effect is not well 
understood 52. It has been shown that c-myc represses C/EBPα expression and it has been 
demonstrated that C/EBPα negatively regulates c-myc transcription 53; 54. Recently it was 
demonstrated that c-myc inhibits C/EBPε transcription 43. C/EBPα was previously found to inhibit 
proliferation of adipocytes and hepatocytes 17; 55. In addition, hepatocytes from newborn C/EBPα-
defi cient mice display increased proliferative activity 56. C/EBPα may inhibit the proliferation via 
interaction with E2F or with cdk2 54; 57-59. Therefore, an intriguing possibility is that C/EBPε may 
also inhibit proliferation by binding to c-myc, p21 or other CDK inhibitors.
Another interesting point is the signals delivered by the G-CSFR. There are two models which 
explain the role of cytokines in hematopoiesis. In the stochastic model the only role of cytokines 
is to support survival of the progenitors that express its cognate receptor on their surface 60; 61. 
These receptor-expressing cells are destined to execute an intrinsically preset differentiation 
program. In contrast, the instructive model suggests active roles for lineage-specifi c cytokines in 
directing various differentiation processes 62-64. We show that G-CSF signalling is necessary for 
induction of myeloid differentiation by C/EBPε. Induction of C/EBPε with 4-OHT in the presence 
of survival factor IL-3 was not enough to induce differentiation. Therefore it seems that the G-
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CSF-R provides more than simply survival signals to enable lineage development, indicating that 
inductive signals are involved in lineage differentiation. The G-CSF-R activates several tyrosine 
kinases as well as the JNK-pathway, STAT proteins, and components of the MAPK-pathway 65; 
66
. It is intriguing to know which signals of the G-CSF-R are involved in the differentiation. It is 
possible that the signals presented by the G-CSF-R regulate C/EBPε activity. However, also 
signals involved in other differentiation inducing pathways can be provided. The fi rst tyrosine 
of the G-CSF receptor was shown to be involved in the expression of C/EBPε 43. Further 
experiments with the different tyrosine mutated G-CSF receptors will give new information 
about the signals involved in C/EBPε expression and activation and other signals involved in 
granulocytic differentiation.
Taken together, we showed that activation of the G-CSF-R together with the expression of 
C/EBPε enhances differentiation of 32D cells. Because we used a tamoxifen inducible system 
we were able to show that expression of C/EBPε directly enhances the differentiation in the 
presence of G-CSF. Expression of C/EBPε-ER decreases proliferation of differentiating 32D 
cells compared to differentiation induced by G-CSF alone. This indicates that C/EBPε is involved 
in the growth arrest of differentiating granulocytes. Both G-CSF and C/EBPε are necessary in 
granulocytic differentiation in 32D cells. Further investigation is necessary to elicit the role of 
G-CSF-R signalling in activation of C/EBPε and other signals involved in the differentiation of 
granulocytes.
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General Discussion
Eosinophils play an important role in the pathogenesis of allergic diseases, such as allergic 
asthma. Eosinophils normally constitute only a few percent of circulating leukocytes. Increased 
numbers of eosinophils are found in peripheral blood, tissues, and bronchoalveolar lavage of 
allergic asthma patients 1; 2. In the bone marrow multipotent stem cells can differentiate towards 
mature eosinophils, which is associated with the expression of specifi c genes, coding for e.g. 
the granule proteins. A highly organised network is required to coordinate these events and 
to maintain steady state levels of mature cells, as well as to stimulate the rapid production of 
specifi c cell types when needed. This thesis has focused on the transcription factors involved 
in the regulation of maturation of human eosinophils. An ex-vivo differentiation model was 
developed to study eosinophilopoiesis, and the role of transcription factors during this process 
was investigated. Our fi ndings are discussed here with respect to hematopoietic cell fate 
decisions. 
The maintenance of adequate numbers of terminally differentiated cells during health and disease 
is ultimately regulated by the continuous self-renewal, controlled proliferation, and differentiation 
of hematopoietic stem cells 3; 4. Closely regulated expression of cytokines, growth factors, 
receptors and transcription factors coordinate lineage development. Cytokines and growth 
factors are soluble glycoproteins released by cells, which exerts their activities by high affi nity 
binding to a specifi c receptor 5. Some cytokines promote the growth and survival of progenitors of 
multiple lineages, such as IL-3 and SCF. Other cytokines are more restricted in their actions and 
support the development of a particular lineage, such as G-CSF and TPO, which are involved in 
the development of granulocytes and megakaryocytes respectively 6; 7.
Transcription factors
1. Lineage specifi city: lineage-specifi c transcription factors
During hematopoiesis, cells undergo maturation resulting in a coordinated, cell-specifi c gene-
expression pattern. The pattern of gene-expression within a cell can be established by cell-specifi c 
transcription factors that mediate the net effect of the variety of proliferation and differentiation 
signals which impinge on it. One convenient way to coordinate the expression of many individual 
genes in a terminally differentiated cell is through the guidance of a few cell-specifi c transcription 
factors. Several examples of this situation have been published. A clear example has been found 
in skeletal muscle lineage development. There are four myogenic basic helix-loop-helix (bHLH) 
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factors MyoD, myogenin, Myf5, and MRF 4, which are specifi cally expressed in muscle cells. 
Together with the more general expressed MEF2 these four bHLH factors act cooperatively to 
regulate the expression of skeletal muscle-specifi c genes 8. Expression of one of these factors 
into non-muscle cells results in the activation of the entire program of muscle development. 
Expression of the transcription factors involved in hematopoiesis is not restricted to one 
lineage, indicating that the processes actually governing hematopoietic cell differentiation are 
undoubtedly more complex.
2. Lineage specifi city: unique combinations of transcription factors
The processes leading to differentiation of stem cells to mature hematopoietic cells are 
more complex than simply lineage specifi c expression of a transcription factor. This because 
transcription factors involved in myelopoiesis are not restricted to myeloid cells. Rather than 
being controlled by single master regulators, lineage-specifi c gene expression appears to 
depend on the combination of transcription factors expressed in a particular lineage. PU.1 and 
C/EBPα cooperate to activate the G-CSF receptor; AML-1 and c-myb synergize in the activation 
of the myeloperoxidase gene; PU.1 cooperates with C/EBPα, c-myb and AML-1 in the activation 
of the neutrophil elastase gene promoter.
We found cooperative regulation of the common β chain of the IL-5R by C/EBPα and PU.1 (chapter 
4). Interestingly, we also located an intronic region which was involved in the regulation of the βc 
promoter. This region from +520 to +640 contains a putative GATA-1 binding site at +550. The 
three regions are involved in gene regulation. Mutation of this GATA-1 element will determine 
whether it is indeed responsible for the enhancer activity of this region. The putative regulation 
of the βc promoter by GATA-1 is an interesting concept. The expression of the β-subunit is not 
restricted to one cell type, but is expressed by all myeloid cells. An explanation for this might be 
that specifi c complexes defi ne lineage and differentiation stages. Starting with gene regulation 
by a protein complex in an early progenitor, factors can be replaced, resulting in complexes that 
specify different cell types and differentiation stages. It is possible that in neutrophils, expression 
of the βc is regulated by PU.1 and C/EBP proteins, whereas in eosinophils C/EBP and GATA-1 
control expression (fi gure 1). In addition, since the common β chain is already expressed in early 
progenitors, regulation must be subject to transcription factors already expressed early during 
differentiation. Both PU.1 and GATA-1 are expressed in early progenitors 9; 10. However, PU.1 
and GATA-1 are known to inhibit each others activity 11-14. Probably other transcription factors are 
involved in gene regulation of the βc in early progenitors. 
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2.1 Relative amounts of transcription factors
Beside the presence of a transcription factor, the relative amount of specifi c protein regulators 
appears also to be involved in lineage decisions. Low amounts of a transcription factor present 
in a progenitor results in different cell fate decision compared to progenitors expression a 
high amount of the transcription factor. Interesting is to investigate how that amount of the 
transcription factors is controlled. PU.1 is required for the proper generation of both myeloid and 
lymphoid lineages. The choice of monocyte or B-lineage specifi c gene expression is mediated 
by different concentrations of PU.1. High concentrations direct progenitors towards monocytes, 
whereas low concentrations promote the B-lymphocytes. 
An example of gene activation regulated by relative amount of transcription factor is provided 
by the eosinophil-specifi c EOS47 gene, the avian ortholog of the mammalian melanotransferrin. 
C/EBPα and Ets-1 were found to cooperate in both the binding to, and activation of, the EOS47 
promoter 15. Interestingly, while low levels of GATA-1 enhanced promoter activation by C/EBPα 
and Ets-1, high levels led to a repression. This repression was further enhanced by FOG-1, 
while GATA-1 on its own has little effect 16. This positive and negative regulation of the EOS47 
promoter closely mimics the distribution of the proteins in the hematopoietic system (fi gure 2). 
Figure 1. Regulation of the βc gene during hematopoiesis Is the common β chain different 
regulated during hematopoiesis? Regulation of the βc gene occurs in different cell types. We 
found that different regions of the promoter are involved in the activation. Different transcription 
factor complexes can be involved in the different cell types during differentiation. C/EBP and 
GATA-1 might regulate expression in eosinophils and PU.1 and C/EBP probably activates the 
promoter in neutrophils. GATA-1 and PU.1 are both expressed in progenitors, but at a low 
level. 
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2.2 Antagonism between different lineage-specifi c transcription factors 
Over the last years the occurrence of antagonism between different lineage-specifi c transcription 
factors has gained much interest. Transcription factors expressed simultaneously can exert 
inhibitory effects on lineage programs by directly antagonising the action of opposing transcription 
factors. The direct physical interaction and cross-antagonism between GATA and PU.1 has been 
demonstrated 11-14. In addition, the antagonistic relationship between the transcription factor C/
EBPβ and FOG in avian models has been reported at the transcriptional level 16.
It seems that the common myeloid progenitor (CMP) is expressing both GATA-1 and PU.1 at 
similar low levels 9; 10. Probably they are functionally antagonising each other, which results in 
absence of transcription of their lineage-specifi c target genes. When the abundance of one of the 
transcription factors increases, and exceeds that of the other transcription factor, this results in 
the activation of target genes, thereby directing cell fate. A positive auto-regulatory feedback loop 
may then further increase the expression of the transcription factor (see fi gure 3).
Figure 2. Distribution of transcription factors in hematopoietic cells GATA-1 is highly 
expressed in erythrocytes and thrombocytes and at a moderate level in the eosinophil lineage. 
PU.1 expression is more pronounced in the neutrophil and monocyte lineage. FOG-1 is 
expressed in erythrocytes and thrombocytes. C/EBP proteins are expressed in eosinophils and 
neutrophils.
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During eosinophil differentiation there is cross-antagonism between C/EBP proteins and FOG. 
This cross-antagonism between C/EBPβ and FOG has been shown for both the avian EOS47 
gene and the mammalian granule major basic protein (MBP). The interaction of GATA-1 and 
FOG is necessary for terminal erythroid maturation and thrombopoiesis. Prevention of these 
pathways is possibly necessary in eosinophil commitment.
A moderate level of GATA-1 in the cell and the presence of C/EBP proteins are important 
for eosinophil lineage determination 16-18. On the other hand PU.1 is important for eosinophil 
differentiation because PU.1 knockout mice lack eosinophils. There is some evidence that 
eosinophils express small amounts of PU.1, but levels are very low compared to less mature cell 
lines (S.J. Ackerman, unpublished result). Therefore it seems that PU.1 expression is induced 
during the early stages of eosinophilopoiesis, but later during differentiation there is an inhibition 
of PU.1. The presence of GATA-1 proteins in mature eosinophils suggests an antagonism 
between GATA-1 and PU.1 in at some point of the development of eosinophils. 
Figure 3. Cross-antagonistic model of lineage determination In early progenitors, lineage-
specifi c transcription factors representing opposing lineages (A and B) are present at similar low 
levels. Because they cross-antagonise each other neither of their target genes is expressed. 
When the abundance of one of the lineage-specifi c transcription factors increases and exceeds 
the other, target genes are activated.
Target gene B
Target gene A
X
X
B
A
B
A
B
A
Type A cellA
B
A
A
A
Target gene B
Target gene A
X
A
Type B cell
A
B
B
B
B
Target gene B
Target gene AX
B
Discussion
Chapter 7
126
3. Regulation by multiple promoters
As previously mentioned some lineage-specifi c proteins, such as receptors, are already 
expressed in early progenitors even though these progenitors lack lineage specifi c transcription 
factors. An explanation for this might be the involvement of unique combinations of widely 
expressed or even ubiquitous transcription factors and lineage specifi c factors. The c-Jun 
oncoprotein forms a heterodimer with the c-Fos protein to form the AP-1 transcription factor, 
which has been shown to be involved in cell proliferation and differentiation 19; 20. C-jun is an 
early response gene in differentiating myeloid cells and its expression is upregulated during 
differentiation 21; 22. C-jun can also physically interact with PU.1 and this interaction is important 
during myeloid differentiation 23; 24. Interestingly in chapter 3 we found the involvement of an AP-1 
site in the regulation of the eosinophil specifi c IL-5 receptor alpha-subunit. The IL-5Rα promoter 
was described in 1995, and was found to be active in the acute myeloid leukemia cell line AML 
14, but not in the pro-myelocytic HL-60 cell line 25. Interestingly, promoter activity was enhanced 
in eosinophil committed cells. An essential transcription factor binding site was found at 421 bp 
upstream of the transcriptional start site. Recently it was reported that a ubiquitously expressed 
protein, named regulatory factor X (RFX), binds to this site and regulates transcription of the 
IL5Rα gene 26. The crucial AP-1 site reported in chapter 3 is located directly upstream of the 
binding site of RFX. A second promoter (P2) was also identifi ed suggesting that IL-5Rα gene 
expression might be regulated by multiple promoters 27. Promoter activity of this second promoter 
Figure 4. Regulation of the IL-5Rα gene by 2 promoters Regulation of IL-5Rα expression is 
under control of 2 promoters. The fi rst promoter which is activated by the general expressed AP-
1 and RFX factors and a second promoter which seems more involved in terminal differentiated 
cells. The protein (complex) binding to this second promoter is unknown.
Exon 2Exon 1 Exon 4
P1 P2
RFX
AP-1
?
Exon 3
ATG
Chapter 7
126 127
is only regulated in an eosinophil committed HL-60 cell line. In this promoter a 6 bp element is 
required for promoter activity and binds to a protein (complex) specifi c for eosinophilic cells. 
The regulation of other tissue-specifi c and developmentally regulated genes has been shown 
to be dependent on multiple promoters 28-30. It is possible that during eosinophil maturation, an 
alternative use of the promoters may determine stage specifi c expression of the IL-5Rα gene 
(fi gure 4). Early during differentiation IL-5Rα expression is regulated by P1, which is regulated 
by general transcription factors. Although this regulation by general transcription factors is cell 
specifi c, since IL-5Rα is limited to early progenitors, basophils and eosinophils. Therefore 
there must be a specifi c regulation in early progenitors, although this regulation remains to be 
solved. The second promoter, P2, becomes more important during later stages of eosinophil 
development, probably by more lineage-restricted proteins. However, the functional site of 
the second promoter has no match for known transcription factors. It would be interesting to 
know what transcription factor (complex) is involved in the activation of the second promoter. 
Another interesting point is the regulation by these two promoters. Is regulation of IL-5Rα in early 
progenitors under the control of the fi rst promoter and later on directed by the second promoter 
or do they work together in more differentiated cells? Further investigation is necessary for the 
differential regulation of the IL-5Rα during eosinophilopoiesis.
4. Consequences for eosinophilopoiesis
In the lineage commitment of the common myeloid progenitor (CMP) to the different mature cell 
types, the transcription factors PU.1, GATA-1, FOG and C/EBPs seem to be involved. Due to 
the complexity of the role of transcription factors during hematopoietic differentiation, several 
hypotheses can be proposed. First a classical linear model, in which the relative expression 
of the proteins is regulating lineage determination. The expression levels of PU.1 and GATA-
1 decide the fate of the CMP towards the different progenitors. During differentiation, the 
expression of lineage specifi c proteins determines lineage decisions. Expression of C/EBP in 
the GM-progenitor results in production of neutrophils, whereas expression of ICSBP favours 
monocytic differentiation. Eosinophils are formed by moderate expression of GATA-1, and later 
on by the expression of C/EBP proteins. These progenitors have one decision point and become 
mature cells in a linear fashion (fi gure 5 model 1). This is the classical view of hematopoiesis. 
Here we propose an alternative hypothesis (fi gure 5 model 2). In this model we assume that 
the differentiation of cells is more complex and that there might be different ways to for a cell to 
differentiate into an eosinophil. Akashi et al. showed that both CMPs and Granulocyte/Monocyte 
Progenitors can generate eosinophil colonies 31. Very recently it was shown that CD34+ cells 
transduced with GATA-1, committed towards neutrophils, express eosinophil markers 32. In 
our CD34+ culture we also observe eosinophils when cultured under neutrophil conditions and 
neutrophils when cultured under eosinophil conditions (unpublished data). Taken together, this 
might indicate that the bifurcation between eosinophils and neutrophils could be late during 
differentiation.
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Figure 5. Two Models for myeloid differentiation Model 1 is a classical linear model. In 
this model the expression of the proteins is regulating lineage determination. In model 2 we 
assume that the eosinophil differentiation is not a linear process, but that there are different 
ways. In both of these models we did not include the basophil, because the role of transcription 
factors in basophils has not been well investigated yet. Although a progenitor for basophils and 
eosinophils has been reported the identity of the basophil precursor is not clear. CMP: common 
myeloid progenitor. ME-prog.: megakaryocyte and erythrocyte progenitor. Eo-prog.: eosinophil 
progenitor. GM-prog.: granulocyte and monocyte progenitor. Mega: megakaryocyte. Ery: 
erythrocyte. EO: eosinophil. Neutro: neutrophil. Mono: monocyte
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5. From cytokine to transcription factor
Transcription factor function is modulated by numerous infl uences including signals delivered 
by cytokines and growth factors. In contrast to the role of transcription factors in hematopoiesis, 
surprisingly little is known about the role of signalling molecules in this process. Cytokines are 
pleiotropic; they can act on different cells and induce a wide range of responses 5. These multiple 
biological effects can be explained by the range of signalling components and transcription 
factors present in the target cells at the time of stimulation with the cytokine. Therefore it is 
interesting to have a closer look at the role of cytokines on eosinophil differentiation.
Several studies have demonstrated that CD34+ cells cultured in the presence of IL-5 were 
committed to the eosinophil lineage and were capable of forming eosinophil colonies 33 indicating 
that IL-5 promotes growth and differentiation of stem cells to mature eosinophils 34; 35. Binding 
of IL-5 to its receptors rapidly induces activation of multiple intracellular signalling pathways, 
including the Ras-Raf-ERK, the JAK/STAT, the phosphatidylinositol 3-kinase (PKB), and the 
JNK/SAPK and p38 signalling pathways 36; 37. Transcriptional initiation is regulated by altering 
the properties of DNA-binding proteins, such as (de)phosphorylation, DNA-binding activity 
and nuclear localization. Several studies have suggested a potential role of phosphorylation 
in the regulation of C/EBPα activity. In granulocytes activation of the Ras pathway can induce 
phosphorylation of C/EBPα at several sites (S-248, S-277, and S-299) by Protein Kinase C (PKC) 
38; 39
. Phosphorylation of C/EBPα results in an enhanced transactivation, for example of the G-
CSF receptor promoter. In addition, C/EBP proteins have been demonstrated to synergistically 
activate transcription the oncostatin M promoter with STAT5, which itself is activated by IL-5 
induced signalling 40. 
How the signalling pathways activated by IL-5 could be involved in the regulation of eosinophil 
differentiation is still intriguing. In granulocytes, G-CSF induces the expression of C/EBPα and 
C/EBPε during differentiation, although the factors regulating this expression remain unclear 
(41, chapter 6). Whether IL-5 is involved in the regulation of C/EBP expression is not known. 
Expression of C/EBPε alone is not suffi cient for neutrophilic differentiation, indicating that other 
signals delivered by the G-CSF-R are involved in this process. Since in neutrophils G-CSF 
signalling is necessary for differentiation, this might indicate that in eosinophil additional IL-5 
induced signals are also involved in the regulation of maturation. Additional signals from the IL-
5R involved in eosinophil differentiation should be specifi c. This could be potentially established 
by signals generated by the eosinophil specifi c alpha-subunit.
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6 Stochastic versus inductive
There is scarce data available concerning the molecular mechanisms regulating expression of 
key transcription factors, which leads to controversy about cell fate decisions in hematopoiesis. 
For example, do cytokines instruct target cells to commit to particular blood lineages (the 
inductive model) or do they simply “select” cells that already have chosen a particular path that 
includes the expression of the lineage restricted receptors (the stochastic model). 
The stochastic model implies that lineage decisions in hematopoiesis arise by chance and 
that growth factors act simply to promote the survival and growth of cells in which the decision 
has already been made. Stem cell commitment might arise through the co-expression of 
combinations of lineage specifi c transcription factors and hematopoietic growth factor receptors. 
At an early stage of commitment any growth factor may suffi ce because the transcription 
factors determine the cellular phenotype. Subsequently, the transcription factors will increase 
the probability of expression of lineage-restricted growth factor receptors, further reinforcing the 
commitment event. 
The inductive model suggests that the lineage-specifi c genes are expressed in response to 
an appropriate external stimulus. In response to that stimulus, they must rapidly increase the 
transcription of lineage specifi c genes. Such a mechanism can only operate if most of the 
genes required for hematopoietic lineages are in open chromatin in stem cells and available for 
transcription. Indeed, Hu et al found evidence of a so-called promiscuous phase of multi-lineage 
gene expression in which myeloid and erythroid lineage genes, including growth factor receptors, 
are co-expressed 10. 
Many lineage-specifi c transcription factors are involved in gene regulation of lineage specifi c 
receptors, e.g. C/EBPα and PU.1 in G-CSF-R regulation 41. In chapter 5, we showed that 
inhibition of C/EBP transcription factors leads to the down-regulation of the βc. In chapter 6 we 
show that for granulocyte differentiation both C/EBPε and G-CSF are involved. G-CSF is able 
to induce granulocytic differentiation by induction of C/EBPε. However, C/EBPε needs G-CSF 
stimulation to rapidly induce granulocytic differentiation. This stimulus can both activate C/EBPε 
and provide additional signals involved in granulocytic differentiation. 
Are cytokines responsible for lineage commitment or are transcription factors the basis of lineage 
determination? Evidence for the role of cytokines and cytokine receptors in hematopoiesis has 
come from studies in knockout mice. The IL-5-/-, IL-5Rα-/-, β
c
-/-
 and β
c
/IL-3 double knock-out mice 
retain lower, but detectable levels of eosinophils 42-44. This indicates that in the absence of the 
specifi c cytokine, differentiation might occur, albeit at a low effi ciency. On the other hand C/
EBPα and C/EBPε knockout mice do not have mature eosinophils demonstrating that the lack 
of transcription factors involved in the regulation of differentiation leads to a block of eosinophil 
production. In chapter 6 we show that over-expression of C/EBPε could induce granulocytic 
differentiation, however in the presence of both C/EBPε and G-CSF signalling, differentiation 
occurs more rapidly. 
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We propose a model for the stochastic and inductive processes during hematopoiesis. The 
initial steps of stem cell differentiation appear to involve the stochastic expression of specifi c 
transcription factors and subsequent induction of lineage-restricted receptors. Therefore these 
cells are able to respond to external signals from cytokines. Cytokines than act to expand 
the population of lineage committed progenitor cells. Therefore in the absence of the specifi c 
cytokine, terminal differentiation might occur but at a very low effi ciency (fi gure 6).
Discussion
e.g. G-CSF / IL-5
Differentiation
Proliferation
e.g. Transcription factors + IL-3
Stochastic processes
Inductive processes
Figure 6. Stochastic or Inductive In this model we show that differentiation is a result of 
stochastic processes in which the programmed cell differentiate and the “inductive model” is 
involved in the proliferation during terminal differentiation. 
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Hematopoiesis
Een volwassen mens heeft ongeveer vijf liter bloed waarin zich miljarden cellen bevinden. 
Deze cellen zijn onder te verdelen op basis van hun verschillende functies: witte bloedcellen 
(afweer tegen ziekteverwekkers), rode bloedcellen (zuurstoftransport) en bloedplaatjes (stolling 
van het bloed). Bloedcellen leven niet lang en daarom moeten er dagelijks miljarden cellen 
worden bijgemaakt. Deze massa productie van bloedcellen (hematopoiesis) vind plaats in het 
beenmerg, de holten van onze botten. De verschillende soorten cellen ontstaan uit stamcellen. 
Het belangrijkste kenmerk van stamcellen, naast het feit dat ze zich kunnen ontwikkelen tot de 
verschillende bloedcellen, is dat ze zichzelf kunnen vernieuwen. Hierdoor zijn er gedurende het 
hele leven cellen aanwezig die zorgen voor de continue aanmaak van nieuwe bloedcellen. Een 
stamcel kan zich via een tussenfase van voorlopercel ontwikkelen tot elk gewenst type bloedcel 
(zie hoofdstuk 1, fi guur 3). Dit proces van ‘volwassen worden’ van een cel wordt differentiatie 
genoemd. Dit gecompliceerde proces wordt beheerst door mechanismen die ervoor zorgen 
dat juist díe bloedcellen worden aangemaakt waaraan de behoefte het grootst is en dat de 
hoeveelheden bloedcellen in het bloed constant blijven. Hierbij spelen hematopoietische 
groeifactoren, regulerende eiwitten, een rol. Ook bepaalde bindweefselcellen in het beenmerg, 
de steuncellen, vervullen hierbij een functie.
Eosinofi ele granulocyten
Eosinofi ele granulocyten (eo’s) zijn witte bloedcellen die een korte periode in de bloedbaan 
aanwezig zijn, maar dan uittreden naar het weefsel. Mede daardoor maken eo’s maar een klein 
deel van de celpopulatie in het bloed uit. Eo’s danken hun naam aan het feit dat ze voor het eerst 
werden gekleurd met de kleurstof eosin. Eosin kleurt de basische eiwitten in de korrels (granula) 
van de cel. Deze korrels zijn een belangrijk kenmerk van eo’s, evenals hun tweelobbige kern.
Het verlaten van de bloedbaan door eo’s is een goed gereguleerd proces en vindt plaats in 
verschillende stappen . In de weefsels aangekomen kunnen eo’s worden geactiveerd, dit leidt tot 
het uitscheiden van schadelijke eiwitten, zuurstofmetabolieten en ontstekingsmediatoren . 
Eosinofi ele granulocyten spelen een positieve rol in infectie’s met wormen, omdat de basische 
eiwitten in de korrels parasieten kunnen vernietigen. Hierdoor worden vervelende infectie’s 
met parasieten voorkomen. Aan de andere kant spelen eo’s een belangrijke, hetzij negatieve 
rol, in de ontwikkeling van allergische ziekten, zoals allergisch astma. Patiënten met allergisch 
astma reageren op stoffen uit de omgeving die normaal gesproken niet schadelijk zijn voor het 
lichaam, bijvoorbeeld huisstofmijt, kattenharen of graspollen. De door eosinofi ele granulocyten 
uitgescheiden stoffen beschadigen weefsel in de longen, met benauwdheid en chronische 
ontstekingen tot gevolg.
Groeifactoren en receptoren
Cellen kunnen communiceren met hun omgeving, dit gebeurd met behulp van verschillende 
moleculen. Een type van die moleculen zijn de cytokinen. Cytokinen zijn eiwitten die worden 
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uitgescheiden en verschillende functie’s hebben, zoals overleving, activatie en differentiatie. Er 
zijn veel verschillende cytokinen, sommige met specifi eke functie’s andere met overlappende 
functie’s. De cytokinen aan de buitenkant van een cel kunnen signalen afgeven aan de cel 
door middel van receptoren. Deze eiwitten hebben een gedeelte buiten de cel om cytokinen te 
kunnen binden en een gedeelte binnen de cel om signalen door te kunnen geven aan andere 
eiwitten. De cytokine, interleukine 5 (IL-5) speelt een belangrijke rol in de groei, differentiatie en 
activatie van eo’s. De receptor voor IL-5 bestaat uit twee componenten. Een β-keten die ook 
wordt gebruikt voor de receptoren voor de cytokinen interleukine-3 en GM-CSF (granulocyte 
macrophage colony stimulating factor) en een α-keten die specifi ek is voor de IL-5 receptor en 
daardoor alleen op eo’s voorkomt.
Transcriptie
Iedere cel maakt verschillende eiwitten voor verschillende doeleinden. Sommige van die eiwitten 
zijn voor iedere cel van belang en komen dan ook in alle cellen voor. Andere eiwitten zijn specifi ek 
voor één bepaalde cel. Wat bepaalt dat in een bepaalde cel een eiwit wel voorkomt en in een 
andere niet? Op het humane genoom (het complete DNA van de mens) liggen ongeveer 30.000-
35.000 genen. Deze genen maken slechts circa 1-2 procent uit van het complete genoom. De 
rest van het DNA bevat regulerende delen (promotor) ofwel delen met een nog onbekende 
functie. Een gen codeert voor één of meerdere eiwitten. De eerste stap om van een gen een 
eiwit te maken noemen we transcriptie. De transcriptie van een gen wordt gereguleerd door de 
binding van transcriptie factoren op specifi eke plaatsen in de promotor. De promotor ligt meestal 
voorafgaand aan een gen op het genoom en is als het ware de regulator van het gen. Sommige 
transcriptie factoren zijn zelf actief, andere hebben de hulp van andere nodig voor volledige 
activatie. De aanwezigheid en activiteit van transcriptie factoren bepalen dus welke eiwitten er 
in een cel voorhanden zijn. Tijdens de vorming van nieuwe bloedcellen zijn transcriptie factoren 
dan ook van belang omdat de aanwezigheid van de verschillende eiwitten bepaalt wat voor een 
soort cel er ontstaat. Er zijn verschillende transcriptie factoren bekend die een rol spelen tijdens 
de hematopoiesis. 
Dit proefschrift
Het eiwit EDN (eosinophil-derived neurotoxin) is te vinden in de specifi eke korrels van 
eosinofi ele granulocyten. In hoofdstuk 2 wordt de regulatie van transcriptie van EDN beschreven. 
Verschillende leden van de C/EBP familie van transcriptie factoren zich kunnen binden aan de 
promotor van het EDN gen. Deze binding van C/EBP eiwitten is van belang voor de transcriptie 
regulatie van EDN. Vernietiging van deze bindingsplaats in de promotor resulteert in een afname 
van de activiteit. 
In hoofdstuk 3 wordt een gebied in de promoter van de α-keten van de IL-5 receptor geïdentifi ceerd 
die betrokken is bij de transcriptie regulatie van dit eiwit. Dit gebied bindt verschillende 
familieleden van de AP-1 familie van transcriptie factoren. Deze AP-1 bindingsplaats reguleert 
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samen met een eerder geïdentifi ceerde bindingsplaats de transcriptie van de α-keten in 
eosinofi ele granulocyten. 
Het is al bekend dat de β-keten wordt gereguleerd door PU.1, een lid van de Ets transcriptie 
factor familie die specifi ek voorkomt in hematopoietische cellen. In hoofdstuk 4 wordt een tweede 
transcriptie activatie gebied geïdentifi ceerd in de promotor van de β-keten. Dit gebied bestaat 
uit twee elementen die zowel C/EBPα, C/EBPβ, als C/EBPε kunnen binden. Verwijdering van dit 
gebied of mutatie van een van de twee C/EBP bindende elementen resulteert in een verlies van 
promotor activiteit. Verder wordt een samenwerking in de activatie van transcriptie tussen PU.1 
en C/EBP eiwitten aangetoond.
In hoofdstuk 5 wordt de rol van C/EBP transcriptie factoren onderzocht tijdens de differentiatie 
van humane CD34+ cellen naar eosinofi ele granulocyten. Hiervoor wordt gebruik gemaakt 
van een differentiatie modelsysteem van stamcel naar eosinofi ele granulocyt. CD34+ 
hematopoietische voorloper cellen worden geïsoleerd uit navelstrengbloed en onder invloed 
van verschillende cytokinen, voornamelijk IL-5, kunnen, we een differentiatie bereiken naar 70% 
eosinofi ele granulocyten. In dit systeem is de C/EBPα expressie hoog gedurende de beginfase 
van de differentiatie en neemt af later tijdens de differentiatie. In tegenstelling tot C/EBPα, neemt 
de expressie van C/EBPε toe tijdens de differentiatie. Een dominant negatieve variant van de C/
EBP familie werd in de differentiërende cellen tot expressie gebracht door middel van retrovirale 
infectie. Remming van de C/EBP familie tijdens differentiatie van eosinofi ele granulocyten 
resulteerde in een afname van de groei en in een blokkade van de differentiatie. Bovendien was 
de expressie van beide ketens van de IL-5 receptor drastisch verlaagd.
Zoals IL-5 betrokken is bij de differentiatie van eo’s reguleert G-CSF (Granulocyte colony-
stimulating factor) de differentiatie van neutrofi ele granulocyten. Het is bekend dat ook in 
neutrofi ele granulocyten C/EBP eiwitten een rol spelen. In hoofdstuk 6 wordt de rol van de 
C/EBPε transcriptie factor in the G-CSF geïnduceerde granulocyte differentiatie onderzocht. 
Hiervoor werd gebruik gemaakt van een induceerbaar systeem, dat zorgt voor een snelle en 
directe activatie van C/EBPε. Expressie van C/EBPε tijdens G-CSF geinduceerde differentiatie 
resulteerde in een versnelling van de differentiatie en een afname van de groei. Stimulatie van 
voorloper cellen met G-CSF resulteert in de vorming van granulocyten, echter dit proces verloopt 
sneller in de aanwezigheid van C/EBPε. Het is echter niet bekend via welke eiwitten de signalen 
van de G-CSF receptor naar C/EBP eiwitten worden doorgegeven.
Uit het onderzoek beschreven in dit proefschrift blijkt dat verschillende transcriptie factoren 
betrokken zijn de vorming van eiwitten in eosinofi ele granulocyten. De rol van C/EBP factoren 
in eo-differentiatie is van groot belang. Remming van deze eiwitten zorgt ervoor dat er geen 
eo’s ontstaan, maar C/EBP eiwitten komen ook in andere cellen voor. Dit betekent dat alleen 
de aanwezigheid van C/EBP eiwiitten niet bepalend is voor de vorming van eo’s. Het lijkt er dan 
ook op dat een complex netwerk van transcriptie factoren en cytokinen bepaald welke cel er 
gevormd wordt.
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